<SEC-DOCUMENT>0001193125-26-084012.txt : 20260302
<SEC-HEADER>0001193125-26-084012.hdr.sgml : 20260302
<ACCEPTANCE-DATETIME>20260302060238
ACCESSION NUMBER:		0001193125-26-084012
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20260224
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260302
DATE AS OF CHANGE:		20260302

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Rein Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001420565
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				134196017
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38130
		FILM NUMBER:		26703176

	BUSINESS ADDRESS:	
		STREET 1:		12407 N. MOPAC EXPY.
		STREET 2:		SUITE 250 #390
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78758
		BUSINESS PHONE:		7378021989

	MAIL ADDRESS:	
		STREET 1:		12407 N. MOPAC EXPY.
		STREET 2:		SUITE 250 #390
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78758

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Aileron Therapeutics, Inc.
		DATE OF NAME CHANGE:	20240329

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AILERON THERAPEUTICS INC
		DATE OF NAME CHANGE:	20071207
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d121919d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:rntx="http://www.aileronrx.com/20260224" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_SecurityExchangeName" name="dei:SecurityExchangeName" contextRef="duration_2026-02-24_to_2026-02-24">NASDAQ</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2026-02-24_to_2026-02-24" id="ixv-254">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2026-02-24_to_2026-02-24">0001420565</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="rntx-20260224.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2026-02-24_to_2026-02-24"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001420565</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-02-24</xbrli:startDate> <xbrli:endDate>2026-02-24</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, DC 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2026-02-24_to_2026-02-24" id="ixv-265">8-K</ix:nonNumeric></span></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2026-02-24_to_2026-02-24" format="ixt:datemonthdayyearen" id="ixv-266">February 24, 2026</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2026-02-24_to_2026-02-24" id="ixv-267">REIN THERAPEUTICS, INC.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact Name of Registrant as Specified in Its Charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2026-02-24_to_2026-02-24" format="ixt-sec:stateprovnameen" id="ixv-268">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2026-02-24_to_2026-02-24" id="ixv-269">001-38130</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2026-02-24_to_2026-02-24" id="ixv-270">13-4196017</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(State or Other Jurisdiction<br/>of Incorporation)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Commission<br/>File Number)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2026-02-24_to_2026-02-24" id="ixv-271">12407 N. Mopac Expy.</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2026-02-24_to_2026-02-24" id="ixv-272">Suite 250</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine3" contextRef="duration_2026-02-24_to_2026-02-24" id="ixv-273">#390</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2026-02-24_to_2026-02-24" id="ixv-274">Austin</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2026-02-24_to_2026-02-24" format="ixt-sec:stateprovnameen" id="ixv-275">Texas</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2026-02-24_to_2026-02-24" id="ixv-276">78758</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of principal executive offices)</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2026-02-24_to_2026-02-24" id="ixv-277">(737)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2026-02-24_to_2026-02-24" id="ixv-278">802-1989</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code)</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">N/A</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions.</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2026-02-24_to_2026-02-24" format="ixt-sec:boolballotbox" id="ixv-279">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2026-02-24_to_2026-02-24" format="ixt-sec:boolballotbox" id="ixv-280">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2026-02-24_to_2026-02-24" format="ixt-sec:boolballotbox" id="ixv-281">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2026-02-24_to_2026-02-24" format="ixt-sec:boolballotbox" id="ixv-282">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c)</span></p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Securities registered pursuant to Section 12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br/>on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2026-02-24_to_2026-02-24" id="ixv-283">Common stock: Par value $.001</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2026-02-24_to_2026-02-24" id="ixv-284">RNTX</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <span style=" -sec-ix-hidden:Hidden_dei_SecurityExchangeName">Nasdaq Capital Market</span> </td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:10pt; margin-bottom:0pt; margin-right:11%; font-size:10pt; font-family:Times New Roman;text-align:right">Emerging growth company&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2026-02-24_to_2026-02-24" format="ixt-sec:boolballotbox" id="ixv-285">&#9744;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#8194;&#9744;</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;1.01 Entry into a Definitive Material Agreement. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;24 and 27, 2026, Rein Therapeutics,&#160;Inc. (the &#8220;Company&#8221;) entered into separate securities purchase agreements (each a &#8220;Purchase Agreement&#8221;) with three institutional investors pursuant to which the Company issued and sold to the investors, in a private placement, unsecured promissory notes in the aggregate original principal amount of $2,875,000 (each a &#8220;Note&#8221;). Pursuant to the Purchase Agreements, the Company issued and sold the Notes to the investors for the aggregate purchase price of $2,300,000, inclusive of an original issue discount of 20%. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Notes have a stated maturity date of the earlier of (i)&#160;the date of the closing of the next issuance and sale of securities of the Company, in a single transaction or series of related transactions, to investors resulting in gross proceeds to the Company of at least $10,000,000 (exclusive of the Note proceeds) or (ii)&#160;June&#160;30, 2026. The Company&#8217;s obligations under the Notes are unsecured. There is no interest payable under the Notes other than the 20% original issue discount. The Purchase Agreements contain representations, warranties, covenants and other terms customary for agreements of such nature. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;2.03 Creation of a Direct Financial Obligation or an Obligation under an <span style="white-space:nowrap">Off-Balance</span> Sheet Arrangement of a Registrant. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information set forth under Item 1.01 of this Current Report on <span style="white-space:nowrap">Form&#160;8-K</span> is hereby incorporated by reference in its entirety. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;3.02 Unregistered Sales of Equity Securities. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information set forth under Item 1.01 of this Current Report on <span style="white-space:nowrap">Form&#160;8-K</span> is incorporated herein by reference. The Notes sold pursuant to the Purchase Agreements were offered and sold pursuant to exemptions from the registration requirements of the Securities Act of 1933, as amended, afforded by Section&#160;4(a)(2)&#160;thereof and Rule&#160;506 of Regulation D promulgated thereunder, for the sale of securities not involving a public offering. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;9.01 Financial Statements and Exhibits. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(d) Exhibits</p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following exhibits are filed with this report: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:5%"/>
<td style="width:92%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Exhibit</span><br/><span style="font-weight:bold">Number</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Exhibit Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">4.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d121919dex101.htm">Form of Unsecured Promissory Note (Included in Exhibit&#160;10.1) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d121919dex101.htm">Form of Securities Purchase Agreement between the Registrant and the Investors </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0">


<tr>

<td style="width:47%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:46%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="5"><span style="font-weight:bold">REIN THERAPEUTICS, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Dated: March&#160;2, 2026</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">/s/ Brian Windsor</span></p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Brian Windsor, Ph.D.,</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">President and Chief Executive Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d121919dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES PURCHASE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This SECURITIES PURCHASE AGREEMENT (this &#8220;<B>Agreement</B>&#8221;) is dated as of February&nbsp;____, 2026, by and between Rein
Therapeutics, Inc., a Delaware corporation (the &#8220;<B>Company</B>&#8221;), and _____________________, including its successors and assigns (&#8220;<B>Purchaser</B>). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Company and the Purchaser are executing and delivering this Agreement in reliance upon the exemption from securities
registration afforded by Section&nbsp;4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated under the Securities Act; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Company desires to sell to the Purchaser, and the Purchaser desires to purchase from the Company, an unsecured promissory
note substantially in the form attached hereto as <U>Exhibit</U><U></U><U>&nbsp;A</U> (the &#8220;<B>Note</B>&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>,
this Note is one of a series of other unsecured promissory notes (&#8220;<B>Other Notes</B>&#8221;) substantially in the form attached hereto as <U>Exhibit A</U> in the aggregate principal amount of up to $5,500,000 inclusive of this Note and an
Other Note in the principal amount of $2,500,000 sold in January 2026. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, in consideration of the mutual agreements,
representations, warranties and covenants herein contained, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and the Purchaser agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Definitions</U>. As used in this Agreement, the following terms shall have the following respective meanings: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Affiliate</B>&#8221; means, with respect to any Person, any other Person that, directly or indirectly through one or more
intermediates, controls, is controlled by or is under common control with such Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Agreement</B>&#8221; has the meaning set
forth in the recitals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Amended and Restated Bylaws</B>&#8221; means the Bylaws of the Company, as currently in effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Benefit Plan</B>&#8221; or &#8220;<B>Benefit Plans</B>&#8221; means employee benefit plans as defined in Section&nbsp;3(3) of ERISA
and all other employee benefit practices or arrangements, including, without limitation, any such practices or arrangements providing severance pay, sick leave, vacation pay, salary continuation for disability, retirement benefits, deferred
compensation, bonus pay, incentive pay, stock options or other stock-based compensation, hospitalization insurance, medical insurance, life insurance, scholarships or tuition reimbursements, maintained by the Company or to which the Company or any
of its subsidiaries is obligated to contribute for employees or former employees of the Company and its subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Board of
Directors</B>&#8221; means the board of directors of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Business Day</B>&#8221; means any day except any Saturday,
any Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Closing</B>&#8221; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.1</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Closing Date</B>&#8221; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.1</U>.<SUP
STYLE="font-size:75%; vertical-align:top"> </SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Code</B>&#8221; means the U.S. Internal Revenue Code of 1986, as amended.
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Common Stock</B>&#8221; means the Company&#8217;s $0.001 par value common stock.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Common Stock Equivalents</B>&#8221; means any securities of the Company that would entitle the holder thereof to acquire at any
time Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible into or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Company</B>&#8221; has the meaning set forth in the recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Confidential Data</B>&#8221; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.32</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Disclosure Document</B>&#8221; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.3</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Drug Regulatory Agency</B>&#8221; means the U.S. Food and Drug Administration (&#8220;<B>FDA</B>&#8221;) or other foreign, state,
local or comparable governmental authority responsible for regulation of the research, development, testing, manufacturing, processing, storage, labeling, sale, marketing, advertising, distribution and importation or exportation of drug or
biological products and drug or biological product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Environmental Laws</B>&#8221; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;3.15</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>ERISA</B>&#8221; means the U.S. Employee Retirement Income Security Act of 1974, as
amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Exchange Act</B>&#8221; means the U.S. Securities Exchange Act of 1934, as amended, and all of the rules and
regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Financial Statements</B>&#8221; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;3.8(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>GAAP</B>&#8221; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;3.8(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>GDPR</B>&#8221; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.33</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Governmental Authorizations</B>&#8221; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.11</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Indemnified Person&#8221; </B>has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.7</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Intellectual Property</B>&#8221; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.10</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>IT Systems</B>&#8221; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.32</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Material Adverse Effect</B>&#8221; means any change, event, circumstance, development, condition, occurrence or effect that,
individually or in the aggregate, (a)&nbsp;was, is, or would reasonably be expected to be, materially adverse to the business, financial condition, properties, assets, liabilities, stockholders&#8217; equity or results of operations of the Company
and its subsidiaries, taken as a whole, or (b)&nbsp;materially delays or materially impairs the ability of the Company to comply, or prevents the Company from complying, with its obligations under this Agreement, the other Transaction Agreements, or
with respect to the Closing, or would reasonably be expected to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Nasdaq</B>&#8221; means the Nasdaq Stock Market LLC.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>National Exchange</B>&#8221; means any of the following markets or exchanges on which the Common Stock is listed or quoted for
trading on the date in question, together with any successor thereto: the NYSE American, The New York Stock Exchange, The Nasdaq Global Market, The Nasdaq Global Select Market and The Nasdaq Capital Market. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Person</B>&#8221; means an individual, partnership, corporation, limited liability
company, business trust, joint stock company, trust, unincorporated association, joint venture or any other entity or organization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Personal Data</B>&#8221; means the following data used in connection with the Company&#8217;s and its subsidiaries&#8217; businesses
and in their possession or control: (i)&nbsp;a natural person&#8217;s name, street address, telephone number, <FONT STYLE="white-space:nowrap">e-mail</FONT> address, photograph, social security number or other tax identification number,
driver&#8217;s license number, passport number, credit card number or bank information; (ii)&nbsp;information that identifies or may reasonably be used to identify an individual; (iii)&nbsp;any information that would qualify as &#8220;protected
health information&#8221; under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act (collectively, &#8220;<B>HIPAA</B>&#8221;); and (iv)&nbsp;any
information that would qualify as &#8220;personal data,&#8221; &#8220;personal information&#8221; (or similar term) under the Privacy Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Privacy Laws</B>&#8221; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.33</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Privacy Statements</B>&#8221; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.33</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Process</B>&#8221; or &#8220;<B>Processing</B>&#8221; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.33</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Purchaser</B>&#8221; has the meanings set forth in the recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Regulatory Agencies</B>&#8221; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.20</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Restated Certificate of Incorporation</B>&#8221; means the Certificate of Incorporation of the Company, as currently in effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Rule 144</B>&#8221; means Rule 144 promulgated by the SEC pursuant to the Securities Act, as such Rule may be amended from time to
time, or any similar rule or regulation hereafter adopted by the SEC having substantially the same effect as such Rule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>SEC</B>&#8221; means the U.S. Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#8220;SEC Reports</B>&#8221; means (a)&nbsp;the Company&#8217;s most recently filed Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> and (b)&nbsp;all Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> or Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed or furnished (as applicable) by the
Company following the end of the most recent fiscal year for which an Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> has been filed and prior to the execution of this Agreement, together in each case with any documents
incorporated by reference therein or exhibits thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Securities Act</B>&#8221; means the U.S. Securities Act of 1933, as
amended, and all of the rules and regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Studies</B>&#8221; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;3.20.</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Tax</B>&#8221; or &#8220;<B>Taxes</B>&#8221; means any and all federal, state, local,
foreign and other taxes, levies, fees, imposts, duties and charges of whatever kind (including any interest, penalties or additions to the tax imposed in connection therewith or with respect thereto), whether or not imposed on the Company or its
subsidiaries (if any) including, without limitation, taxes imposed on, or measured by, income, franchise, profits or gross receipts, and also ad valorem, value added, sales, use, service, real or personal property, capital stock, license, payroll,
withholding, employment, social security, workers&#8217; compensation, unemployment compensation, utility, severance, production, excise, stamp, occupation, premium, windfall profits, transfer and gains taxes and customs duties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Tax Returns</B>&#8221; means returns, reports, information statements and other
documentation (including any additional or supporting material) filed or maintained, or required to be filed or maintained, in connection with the calculation, determination, assessment or collection of any Tax and shall include any amended returns
required as a result of examination adjustments made by the Internal Revenue Service or other Tax authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B>Transaction
Agreements</B>&#8221; means this Agreement and the Note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Purchase and Sale of Note</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1 <U>Purchase and Sale</U>. On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to sell,
and the Purchaser, agree to purchase the Note in the original principal amount of $________for the purchase price of $________ (&#8220;<B>Purchase Price</B>&#8221;), inclusive of an original issue discount of twenty percent (20%). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2 <U>Closing</U>. Subject to the satisfaction or waiver of the conditions set forth in <U>Section</U><U></U><U>&nbsp;6</U> of this
Agreement, the closing of the purchase and sale of the Note (the &#8220;<B>Closing</B>&#8221; and the date on which the Closing occurs, the &#8220;<B>Closing Date</B>&#8221;) shall occur remotely via the exchange of documents and signatures at such
time as agreed to by the Company and the Purchaser but (i)&nbsp;in no event earlier than the first Business Day after the date of this Agreement and (ii)&nbsp;in no event later than the fifth Business Day after the date of this Agreement. At the
Closing, the Note shall be issued and registered in the name of the Purchaser, or in such nominee name(s) as designated by the Purchaser, against payment to the Company of the Purchase Price by wire transfer to the Company of immediately available
funds, at or prior to the Closing, in accordance with wire instructions provided by the Company to the Purchaser at least one Business Day prior to the Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Representations and Warranties of the Company</U>. Except as set forth in the SEC Reports, the Company hereby represents and warrants to
the Purchaser that the statements contained in this <U>Section</U><U></U><U>&nbsp;3</U> are true and correct as of the date of this Agreement and as of the Closing Date (except for the representations and warranties that speak as of a specific date,
which shall be made as of such date). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1 <U>Organization and Power</U>. The Company is a corporation duly organized, validly existing
and in good standing under the laws of the State of Delaware, has the requisite power and authority to own, lease and operate its properties and to carry on its business as now conducted and described in the SEC Reports and is qualified to do
business in each jurisdiction in which the character of its properties or the nature of its business requires such qualification, except where such failure to be in good standing or to have such power and authority or to so qualify would not
reasonably be expected to have a Material Adverse Effect. Each of the Company&#8217;s subsidiaries is (i)&nbsp;duly incorporated and validly existing and in good standing under the laws of the jurisdiction of its incorporation and has the requisite
power and authority to carry on its business as now conducted and to own or lease its properties and (ii)&nbsp;qualified to do business as a foreign corporation and in good standing in each jurisdiction in which such qualification is required,
except in each case as would not reasonably be expected to have a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.2 <U>Capitalization</U>. The Company&#8217;s
disclosure of its authorized, issued and outstanding capital stock in the SEC Reports containing such disclosure was accurate in all material respects as of the date indicated in such SEC Reports. All of the issued and outstanding shares of Common
Stock have been duly authorized and validly issued and are fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> None of the outstanding </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shares of capital stock of the Company were issued in violation of any preemptive or other similar rights of any securityholder of the Company which have not been waived, and such shares were
issued in compliance in all material respects with applicable state and federal securities law and any rights of third parties. There are no outstanding rights (including, without limitation, <FONT STYLE="white-space:nowrap">pre-emptive</FONT>
rights), warrants or options to acquire, or instruments convertible into or exchangeable for, any shares of capital stock or other equity interest in the Company or any of its subsidiaries, or any contract, commitment, agreement, understanding or
arrangement of any kind relating to the issuance of any capital stock of the Company or any such subsidiary, any such convertible or exchangeable securities or any such rights, warrants or options, except as set forth in the SEC Reports; the capital
stock of the Company conforms in all material respects to the description thereof contained in the SEC Reports; and all the outstanding shares of capital stock or other equity interests of each subsidiary owned, directly or indirectly, by the
Company have been duly and validly authorized and issued, are fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> (except, in the case of any foreign subsidiary, for directors&#8217; qualifying shares) and are owned directly or
indirectly by the Company, free and clear of any lien, charge, encumbrance, security interest, restriction on voting or transfer or any other claim of any third party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.3 <U>Authorization</U>. The Company has all requisite corporate power and authority to enter into the Transaction Agreements and to carry
out and perform its obligations under the terms of the Transaction Agreements, including the issuance and sale of the Note. All corporate action on the part of the Company, its officers, directors and stockholders necessary for the authorization of
the Note, the authorization, execution, delivery and performance of the Transaction Agreements and the consummation of the transactions contemplated herein, including the issuance and sale of the Note has been taken, including, without limitation,
the approval of the Board of Directors (or a committee thereof). This Agreement has been duly executed and delivered by the Company and, assuming the due authorization, execution and delivery by the Purchaser of this Agreement and that this
Agreement constitutes the legal, valid and binding agreement of the Purchaser, this Agreement and the Note constitutes a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except as such
enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium and similar laws relating to or affecting creditors generally or by general equity principles (regardless of whether such enforceability is considered in a
proceeding in equity or at law). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.4 <U>No Conflict</U>. The execution, delivery and performance of the Transaction Agreements by the
Company, the issuance and sale of the Note and the consummation of the other transactions contemplated by the Transaction Agreements will not (i)&nbsp;violate any provision of the Restated Certificate of Incorporation or Amended and Restated Bylaws
of the Company, (ii)&nbsp;conflict with or result in a violation of or default (with or without notice or lapse of time, or both) under, or give rise to a right of termination, cancellation or acceleration of any obligation, a change of control
right or to a loss of a benefit under any agreement or instrument, credit facility, franchise, license, judgment, order, statute, law, ordinance, rule or regulations, applicable to the Company or any of its subsidiaries or their respective
properties or assets,&nbsp;or (iii) result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company or any of its subsidiaries is subject
(including federal and state securities laws and regulations) and the rules and regulations of any self-regulatory organization to which the Company or its securities are subject, or by which any property or asset of the Company or any of its
subsidiaries is bound or affected, except, in the case of clauses (ii) and (iii), as would not, individually or in the aggregate, be reasonably expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.5 <U>Consents</U>. Assuming the accuracy of the representations and warranties of the Purchaser set forth in
<U>Section</U><U></U><U>&nbsp;4</U> hereof, no consent, approval, authorization, filing with or order of or registration with, any court or governmental agency or body is required in connection with the authorization, execution or delivery by the
Company of the Transaction Agreements, the issuance and sale of the Note and the performance by the Company of its other obligations under the Transaction Agreements, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
except (a)&nbsp;as have been or will be obtained or made under the Securities Act or the Exchange Act, (b)&nbsp;customary post-closing filings with the SEC or pursuant to state securities laws in
connection with the offer and sale of the Note by the Company in the manner contemplated herein, which will be filed on a timely basis, or (c)&nbsp;such that the failure of which to obtain would not have a Material Adverse Effect. All notices,
consents, authorizations, orders, filings and registrations which the Company is required to deliver or obtain prior to the Closing pursuant to the preceding sentence have been obtained or made or will be delivered or obtained or effected, and shall
remain in full force and effect, on or prior to the Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.6 <U>SEC Filings; Financial Statements</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Company has filed all forms, statements, certifications, reports and documents required to be filed by it with the SEC under
Section&nbsp;13, 14(a) and 15(d) of the Exchange Act for the one year preceding the date of this Agreement and is in compliance with General Instruction I.A.3 of Form <FONT STYLE="white-space:nowrap">S-3.</FONT> As of the time it was filed with the
SEC (or, if amended or superseded by a filing prior to the date of this Agreement, then on the date of such filing), each of the filed SEC Reports complied in all material respects with the applicable requirements of the Exchange Act , and, as of
the time they were filed, none of the filed SEC Reports contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the
circumstances under which they were made, not misleading. There are no outstanding or unresolved comments from the SEC staff with respect to the SEC Reports. To the Company&#8217;s knowledge, none of the SEC Reports are the subject of an ongoing SEC
review. The interactive data in eXtensible Business Reporting Language included in the SEC Reports fairly presents the information called for in all material respects and has been prepared in accordance with the SEC&#8217;s rules and guidelines
applicable thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The consolidated financial statements of the Company included in the SEC Reports (collectively, the
&#8220;<B>Financial Statements</B>&#8221;) comply in all material respects with applicable accounting requirements and the rules and regulations of the SEC with respect thereto as in effect at the time of filing (or to the extent corrected by a
subsequent restatement) and fairly present in all material respects the consolidated financial position of the Company and its subsidiaries as of the dates indicated, and the results of its operations and cash flows for the periods therein
specified, and have been prepared in accordance with United States generally accepted accounting principles (&#8220;<B>GAAP</B>&#8221;) applied on a consistent basis throughout the periods therein specified ((except as otherwise noted therein, and
except that any unaudited financial statements may not contain certain footnotes and are subject to normal and recurring <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments). Except as set forth in the Financial Statements filed prior to
the date of this Agreement, the Company has not incurred any liabilities, contingent or otherwise, except (i)&nbsp;those incurred in the ordinary course of business, consistent with past practices since the date of such financial statements,
(ii)&nbsp;for this Note and the Other Notes or (iii)&nbsp;liabilities not required under GAAP to be reflected in the Financial Statements, in either case, none of which, individually or in the aggregate, have had or would reasonably be expected to
have a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.7 <U>Absence of Changes</U>. Since December&nbsp;31, 2024, (a) the Company has conducted its business
only in the ordinary course of business and there have been no material transactions entered into by the Company or any of its subsidiaries (except for the execution and performance of this Agreement and the discussions, negotiations and
transactions related thereto); (b) no material change to any material contract or arrangement by which the Company or any of its subsidiaries is bound or to which any of its assets or properties is subject has been entered into that has not been
disclosed in the SEC Reports; and (c)&nbsp;there has not been any other event or condition of any character that has had or would reasonably be expected to have a Material Adverse Effect; provided, however, that none of the following will be deemed
in themselves, either alone or in combination, to constitute, and that none of the following will be taken into account in determining whether there has been or will be, a Material Adverse Effect under this <U>Section</U><U></U><U>&nbsp;3.9</U>:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) any change generally affecting the economy, financial markets or political, economic or regulatory conditions in the United States or
any other geographic region in which the Company conducts business, provided that the Company is not disproportionately affected thereby; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) general financial, credit or capital market conditions, including interest rates or
exchange rates, or any changes therein, provided that the Company is not disproportionately affected thereby; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) any change that
generally affects industries in which the Company and its subsidiaries conduct business, provided that the Company is not disproportionately affected thereby; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) earthquakes, hurricanes, tsunamis, tornadoes, floods, mudslides, fires or other natural disasters, weather conditions, global pandemics,
including the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and related strains, epidemic or similar health emergency, and other force majeure events in the United States or any other location, provided that the Company is not
disproportionately affected thereby; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) national or international political or social conditions (or changes in such conditions),
whether or not pursuant to the declaration of a national emergency or war, or the occurrence of any military or terrorist attack, provided that the Company is not disproportionately affected thereby; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) material changes in laws after the date of this Agreement; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) in and of itself, any material failure by the Company to meet any published or internally prepared estimates of revenues, expenses,
earnings or other economic performance for any period ending on or after the date of this Agreement (it being understood that the facts and circumstances giving rise to such failure may be deemed to constitute, and may be taken into account in
determining whether there has been, a Material Adverse Effect to the extent that such facts and circumstances are not otherwise described in clauses (i)-(v) of this definition). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.8 <U>Absence of Litigation</U>. There is no action, suit, proceeding, arbitration, claim, investigation, charge, complaint or inquiry
pending or, to the Company&#8217;s knowledge, threatened against the Company or any of its subsidiaries which, individually or in the aggregate, has had or would reasonably be expected to have a Material Adverse Effect, nor are there any orders,
writs, injunctions, judgments or decrees outstanding of any court or government agency or instrumentality and binding upon the Company or any of its subsidiaries that have had or would reasonably be expected to have a Material Adverse Effect.
Neither the Company nor any subsidiary, nor to the knowledge of the Company, any director or officer of the Company or any subsidiary, is, or within the last ten years has been, the subject of any action involving a claim of violation of or
liability under federal or state securities laws relating to the Company or such subsidiary or a claim of breach of fiduciary duty relating to the Company or such subsidiary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.9 <U>Compliance with Law; Permits</U>. Neither the Company nor any of its subsidiaries is in violation of, or has received any notices of
violations with respect to, any laws, statutes, ordinances, rules or regulations of any governmental body, court or government agency or instrumentality, except for violations which, individually or in the aggregate, have not had and would not
reasonably be expected to have a Material Adverse Effect. The Company and its subsidiaries have all required licenses, permits, certificates and other authorizations (collectively, &#8220;<B>Governmental Authorizations</B>&#8221;) from such federal,
state or local government or governmental agency, department or body that are currently necessary for the operation of the business of the Company and its subsidiaries as currently conducted, except where the failure to possess currently such
Governmental Authorizations has not had and is not reasonably expected to have a Material Adverse Effect. Neither the Company nor any subsidiary has received any written (or, to the Company&#8217;s knowledge, oral) notice regarding any revocation or
material modification of any such Governmental Authorization, which, individually or in the aggregate, if the subject of an unfavorable decision, ruling or finding, has or would reasonably be expected to result in a Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.10 <U>Intellectual Property</U>. The Company and its subsidiaries own, or have rights to
use, all material inventions, patent applications, patents, trademarks, trade names, service names, service marks, copyrights, trade secrets, know how (including unpatented and/or unpatentable proprietary of confidential information, systems or
procedures) and other intellectual property as described in the SEC Reports necessary for, or used in the conduct of their respective businesses (including as described in the SEC Reports) (collectively, &#8220;<B>Intellectual Property</B>&#8221;),
except where any failure to own, possess or acquire such Intellectual Property has not had, and would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. The Intellectual Property of the Company and its
subsidiaries has not been adjudged by a court of competent jurisdiction to be invalid or unenforceable, in whole or in part. To the Company&#8217;s knowledge: (i)&nbsp;there are no third parties who have rights to any Intellectual Property,
including no liens, security interests, or other encumbrances; and (ii)&nbsp;there is no infringement by third parties of any Intellectual Property, except, in each case, which, individually or in the aggregate, have not had and would not reasonably
be expected to have a Material Adverse Effect. No action, suit, or other proceeding is pending, or, to the Company&#8217;s knowledge, is threatened: (A)&nbsp;challenging the Company&#8217;s or its subsidiaries&#8217; rights in or to any Intellectual
Property; (B)&nbsp;challenging the validity, enforceability or scope of any Intellectual Property; or (C)&nbsp;alleging that the Company or any of its subsidiaries infringes, misappropriates, or otherwise violates any patent, trademark, trade name,
service name, copyright, trade secret or other proprietary rights of others, except, in each case, which, individually or in the aggregate, have not had and would not reasonably be expected to have a Material Adverse Effect. The Company and its
subsidiaries have complied in all material respects with the terms of each agreement pursuant to which Intellectual Property has been licensed to the Company or any of its subsidiaries in all material respects, and to the Company&#8217;s knowledge
all such agreements are in full force and effect. To the Company&#8217;s knowledge, there are no material defects in any of the patents or patent applications included in the Intellectual Property. The Company and its subsidiaries have taken all
reasonable steps to protect, maintain and safeguard their Intellectual Property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.11 <U>Employee Benefits</U>. Except as would not be
reasonably likely to result in a Material Adverse Effect, each Benefit Plan has been established and administered in accordance with its terms and in compliance with the applicable provisions of ERISA, the Code, and other applicable laws, rules and
regulations. The Company and its subsidiaries are in compliance with all applicable federal, state and local laws, rules and regulations regarding employment, except for any failures to comply that are not reasonably likely, individually or in the
aggregate, to have a Material Adverse Effect. There is no labor dispute, strike or work stoppage against the Company or its subsidiaries pending or, to the knowledge of the Company, threatened which may interfere with the business activities of the
Company, except where such dispute, strike or work stoppage is not reasonably likely, individually or in the aggregate, to have a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.12 <U>Taxes</U>. The Company and its subsidiaries have filed all federal, state and foreign income Tax Returns and other Tax Returns
required to have been filed under applicable law (or extensions have been duly obtained) and have paid all Taxes required to have been paid by them, except for those which are being contested in good faith and except where failure to file such Tax
Returns or pay such Taxes would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. No assessment in connection with United States federal tax returns has been made against the Company. The charges,
accruals and reserves on the books of the Company in respect of any income and corporation tax liability for any years not finally determined are adequate to meet any assessments or reassessments for additional income tax for any years not finally
determined, except to the extent of any inadequacy that would not result in a Material Adverse Effect. No audits, examinations, or other proceedings with respect to any material amounts of Taxes of the Company and its subsidiaries are presently in
progress or have </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
been asserted or proposed in writing without subsequently being paid, settled or withdrawn. There are no liens on any of the assets of the Company. At all times since inception, the Company has
been and continues to be classified as a corporation for U.S. federal income tax purposes. Neither the Company nor any of its subsidiaries has been a United States real property holding corporation within the meaning of Code <FONT
STYLE="white-space:nowrap">Section&nbsp;897(c)-2</FONT> during the period specified in Code Section&nbsp;897(c)(1)(A)(ii). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.13
<U>Environmental Laws</U>. The Company and its subsidiaries (i)&nbsp;are in compliance with any and all applicable foreign, federal, state and local laws and regulations relating to the protection of human health and safety, the environment or
hazardous or toxic substances or wastes, pollutants or contaminants (&#8220;<B>Environmental Laws</B>&#8221;), (ii)&nbsp;have received all permits and other Governmental Authorizations required under applicable Environmental Laws to conduct their
business and (iii)&nbsp;are in compliance with all terms and conditions of any such permit, license or approval, except where such noncompliance with Environmental Laws, failure to receive required permits, licenses or other approvals or failure to
comply with the terms and conditions of such permits, licenses or approvals would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.14 <U>Title</U>. Each of the Company and its subsidiaries has good and marketable title to all personal property owned by it that is
material to the business of the Company, free and clear of all liens, encumbrances and defects except such as do not materially and adversely affect the value of such property and do not materially and adversely interfere with the use made and
proposed to be made of such property by the Company or its subsidiaries, as the case may be. Any real property and buildings held under lease by the Company or its subsidiaries is held under valid, subsisting and enforceable leases with such
exceptions as are not material and do not interfere with the use made and proposed to be made of such property and buildings by the Company or its subsidiaries, as the case may be. The Company does not own any real property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.15 <U>Insurance</U>. The Company carries or is entitled to the benefits of insurance in such amounts and covering such risks that is
customary for comparably situated companies and is adequate for the conduct of its business and the value of its real and personal properties (owned or leased) and tangible assets, and each of such insurance policies is in full force and effect and
the Company is in compliance in all material respects with the terms of such insurance policies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.16 <U>Nasdaq Stock Market</U>. The
issued and outstanding shares of Common Stock are registered pursuant to Section&nbsp;12(b) of the Exchange Act and are listed for trading on the Nasdaq Capital Market under the symbol &#8220;RNTX&#8221;. The Company is in compliance with all
listing requirements of Nasdaq applicable to the Company. As of the date of this Agreement, there is no suit, action, proceeding or investigation pending or, to the knowledge of the Company, threatened against the Company by Nasdaq or the SEC,
respectively, to prohibit or terminate the listing of the Common Stock on the Nasdaq Capital Market or to deregister the Common Stock under the Exchange Act. The Company has taken no action as of the date of this Agreement that is designed to
terminate the registration of the Common Stock under the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.17 <U>Sarbanes-Oxley Act</U>. The Company is in compliance in
all material respects with all applicable requirements of the Sarbanes-Oxley Act of 2002 and applicable rules and regulations promulgated by the SEC thereunder<U>.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.18 <U>Clinical Data and Regulatory Compliance</U>. Except as would not reasonably be expected to result in a Material Adverse Effect:
(i)&nbsp;the preclinical tests and clinical trials and other studies used to support regulatory approval (collectively, &#8220;<B>Studies</B>&#8221;) being conducted by or on behalf of, or sponsored by, the Company or its subsidiaries that are
described in, or the results of which are referred to in, the SEC Reports were (and, if still pending, are being) conducted in all material respects in accordance </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with the protocols, procedures and controls designed and approved for such Studies and with standard medical and scientific research procedures; (ii)&nbsp;each description of the results of such
Studies is accurate and complete in all material respects and fairly presents the data derived from such Studies, and the Company and its subsidiaries have no knowledge of any other studies the results of which are inconsistent with, or otherwise
call into question, the results described or referred to in the SEC Reports; (iii)&nbsp;the Company and its subsidiaries have made all such filings and obtained all such approvals as may be required by the FDA or from any other U.S. federal, state
or local government or foreign government or Drug Regulatory Agency, or Institutional Review Board, each having jurisdiction over biopharmaceutical products (collectively, the &#8220;<B>Regulatory Agencies</B>&#8221;) for the conduct of its business
as described in the SEC Reports; (iv)&nbsp;neither the Company nor any of its subsidiaries has received any notice of, or correspondence from, any of the Regulatory Agencies requiring the termination or suspension of or imposing any clinical hold on
any clinical trials that are described or referred to in the SEC Reports; and (v)&nbsp;the Company and its subsidiaries have each operated and currently are in compliance in all material respects with all applicable rules, regulations and policies
of the Regulatory Agencies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.19 <U>[Reserved.</U><U>]</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.20 <U>Accounting Controls and Disclosure Controls and Procedures</U>. The Company maintains a system of internal control over financial
reporting (as defined in Rules <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f)</FONT> of the Exchange Act) that is designed to comply with the requirements of the Exchange Act applicable to the
Company and provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP, including policies and procedures sufficient to provide reasonable
assurance (i)&nbsp;that the Company maintains records that in reasonable detail accurately and fairly reflect the Company&#8217;s transactions and dispositions of assets, (ii)&nbsp;that transactions are recorded as necessary to permit preparation of
financial statements in accordance with GAAP, (iii)&nbsp;that receipts and expenditures are made only in accordance with authorizations of management and the Board and (iv)&nbsp;regarding prevention or timely detection of the unauthorized
acquisition, use or disposition of the Company&#8217;s assets that could have a material effect on the Company&#8217;s financial statements. Except as disclosed in the Company&#8217;s SEC Reports filed prior to the date of this Agreement, the
Company has not identified any material weaknesses in the design or operation of the Company&#8217;s internal control over financial reporting. The Company&#8217;s &#8220;disclosure controls and procedures&#8221; (as defined in Rules <FONT
STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e)</FONT> of the Exchange Act) are designed to provide reasonable assurance that all information (both financial and
<FONT STYLE="white-space:nowrap">non-financial)</FONT> required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the
rules and forms of the SEC, and that all such information is accumulated and communicated to the Company&#8217;s management as appropriate to allow timely decisions regarding required disclosure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.21 <U>Investment Company Act</U>. The Company is not, and immediately after receipt of payment for the Note will not be, an
&#8220;investment company&#8221; within the meaning of the U.S. Investment Company Act of 1940, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.22 <U>General Solicitation;
No Integration or Aggregation</U>. Neither the Company nor any other person or entity authorized by the Company to act on its behalf has engaged in a general solicitation or general advertising (within the meaning of Regulation D of the Securities
Act) of investors with respect to offer or sale of Note pursuant to this Agreement. The Company has not, directly or indirectly, sold, offered for sale, solicited offers to buy or otherwise negotiated in respect of, any security (as defined in the
Securities Act) which, to its knowledge, is or will be (i)&nbsp;integrated with the offer and sale of the Note pursuant to this Agreement for purposes of the Securities Act or (ii)&nbsp;aggregated with prior offerings by the Company for the purposes
of the rules and regulations of the Nasdaq Capital Market. Assuming the accuracy of the representations and warranties of the Purchaser set forth in <U>Section</U><U></U><U>&nbsp;4</U>, neither </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Company nor any of its Affiliates, its subsidiaries nor any Person acting on their behalf has, directly or indirectly, made any offers or sales of any Company security or solicited any offers
to buy any Company security, under circumstances that would adversely affect reliance by the Company on Section&nbsp;4(a)(2) and/or Rule 506 of Regulation D promulgated thereunder for the exemption from registration for the transactions contemplated
hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.23 <U>Brokers and Finders</U>. Neither the Company nor any other Person authorized by the Company to act on its behalf has
retained, utilized or been represented by any broker or finder in connection with the transactions contemplated by this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.24
<U>Reliance by the Purchaser</U>. The Company has a reasonable basis for making each of the representations set forth in this <U>Section</U><U></U><U>&nbsp;3</U>. The Company acknowledges that the Purchaser will rely upon the truth and accuracy of,
and the Company&#8217;s compliance with, the representations, warranties, agreements, acknowledgements and understandings of the Company set forth herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.25 <U>Anti-Bribery and Anti-Money Laundering Laws</U>. Each of the Company, its subsidiaries and, to the knowledge of the Company, any of
their respective officers, directors, supervisors, managers, agents, or employees are and have at all times been in compliance with and its participation in the offering will not violate: (A)&nbsp;anti-bribery laws, including but not limited to, any
applicable law, rule, or regulation of any locality, including but not limited to any law, rule, or regulation promulgated to implement the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions,
signed December<U></U>&nbsp;17, 1997, including the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.K. Bribery Act 2010, or any other law, rule or regulation of similar purposes and scope; (B)<U></U>&nbsp;anti-money laundering laws,
including, but not limited to, applicable federal, state, international, foreign or other laws, regulations or government guidance regarding anti-money laundering, including, without limitation, Title 18 US. Code sections 1956 and 1957, the Patriot
Act, the Bank Secrecy Act, and international anti-money laundering principles or procedures by an intergovernmental group or organization, such as the Financial Action Task Force on Money Laundering, of which the United States is a member and with
which designation the United States representative to the group or organization continues to concur, all as amended, and any executive order, directive, or regulation pursuant to the authority of any of the foregoing, or any orders or licenses
issued thereunder; or (C)<U></U>&nbsp;except as would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect, any laws with respect to import and export control and economic sanctions, including the U.S.
Export Administration Regulations, the U.S. International Traffic in Arms Regulations, and economic sanctions regulations and executive orders administered by the U.S. Department of the Treasury Office of Foreign Asset Control.<SUP
STYLE="font-size:75%; vertical-align:top"> </SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.26 <U>Cybersecurity</U>. The Company and its subsidiaries&#8217; information
technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, and databases (collectively, &#8220;<B>IT Systems</B>&#8221;) are adequate for, and operate and perform in all material respects as required
in connection with the operation of the business of the Company and its subsidiaries as currently conducted, and are free and clear of all material Trojan horses, time bombs, malware and other malicious code. The Company and its subsidiaries have
implemented and maintained commercially reasonable physical, technical and administrative controls designed to maintain and protect the confidentiality, integrity, availability, privacy and security of all sensitive, confidential or regulated data
(&#8220;<B>Confidential Data</B>&#8221;) used or maintained in connection with their businesses and Personal Data, and the integrity, availability continuous operation, redundancy and security of all IT Systems. To the Company&#8217;s knowledge,
there have been no breaches, outages or unauthorized uses of or accesses to the Company&#8217;s IT Systems, Confidential Data, or Personal Data that would require notification under Privacy Laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.27 <U>Compliance with Data Privacy Laws</U>. The Company and its subsidiaries are, and at
all prior times were, in material compliance with all applicable state, federal and foreign data privacy and security laws and regulations regarding the collection, use, storage, retention, disclosure, transfer, disposal, or any other processing
(collectively &#8220;<B>Process</B>&#8221; or &#8220;<B>Processing</B>&#8221;) of Personal Data, including without limitation HIPAA, the EU General Data Protection Regulation (&#8220;<B>GDPR</B>&#8221;) (Regulation (EU) No.<U></U>&nbsp;2016/679),
all other local, state, federal, national, supranational and foreign laws relating to the regulation of the Company or its subsidiaries, and the regulations promulgated pursuant to such statutes and any state or non-U.S. counterpart thereof
(collectively, the &#8220;<B>Privacy Laws</B>&#8221;). To ensure material compliance with the Privacy Laws, the Company and its subsidiaries have in place, comply with, and take all appropriate steps necessary to ensure compliance in all material
respects with their policies and procedures relating to data privacy and security, and the Processing of Personal Data and Confidential Data (the &#8220;<B>Privacy Statements</B>&#8221;). The Company and its subsidiaries have, except as would not
reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect, at all times since inception provided accurate notice of their Privacy Statements then in effect to its customers, employees, third party vendors and
representatives. None of such disclosures made or contained in any Privacy Statements have been materially inaccurate, misleading, incomplete, or in material violation of any Privacy Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.28 <U>Transactions with Affiliates and Employees</U>. No relationship, direct or indirect, exists between or among the Company or any of its
subsidiaries, on the one hand, and the directors, officers, stockholders, customers or suppliers of the Company, on the other hand, that is required to be described in the SEC Reports that is not so described. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Representations and Warranties of the </U><U>Purchaser</U>. The Purchaser represents and warrants to the Company that the statements
contained in this <U>Section</U><U></U><U>&nbsp;4</U> are true and correct as of the date of this Agreement and the Closing Date: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.1
<U>Organization</U>. The Purchaser is duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization and has the requisite power and authority to own, lease and operate its properties and to carry on its
business as now conducted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.2 <U>Authorization</U>. The Purchaser has all requisite corporate or similar power and authority to enter
into this Agreement and the other Transaction Agreements to which it will be a party and to carry out and perform its obligations hereunder and thereunder. All corporate, member or partnership action on the part of the Purchaser or its stockholders,
members or partners necessary for the authorization, execution, delivery and performance of this Agreement and the other Transaction Agreements to which it will be a party and the consummation of the other transactions contemplated in this Agreement
has been taken. The execution, delivery and performance by the Purchaser of the Transaction Agreements to which the Purchaser is a party has been duly authorized and each has been duly executed. Assuming this Agreement constitutes the legal and
binding agreement of the Company, this Agreement constitutes a legal, valid and binding obligation of the Purchaser, enforceable against the Purchaser in accordance with its respective terms, except as such enforceability may be limited or otherwise
affected by bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and/or similar laws relating to or affecting the rights of creditors generally or by general equity principles (regardless of whether such enforceability is
considered in a proceeding in equity or at law). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.3 <U>No Conflict</U><U>s</U>. The execution, delivery and performance of the
Transaction Agreements by the Purchaser, the purchase of the Note in accordance with their terms and the consummation by the Purchaser of the other transactions contemplated hereby will not conflict with or result in any violation of, breach or
default by the Purchaser (with or without notice or lapse of time, or both) under, conflict with, or give rise to a right of termination, cancellation or acceleration of any obligation, a change of control right or to a loss of a material benefit
under (i)&nbsp;any provision of the organizational documents of the Purchaser, including, without limitation, its incorporation or formation papers, bylaws, indenture of trust or partnership or operating agreement, as may be applicable or
(ii)&nbsp;any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agreement or instrument, undertaking, credit facility, franchise, license, judgment, order, ruling, statute, law, ordinance, rule or regulations, applicable to such Purchaser or its respective
properties or assets, except, in the case of clause (ii), as would not, individually or in the aggregate, be reasonably expected to materially delay or hinder the ability of the Purchaser to perform its obligations under the Transaction Agreements.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.4 <U>Residency</U>. The Purchaser&#8217;s residence (if an individual) or offices in which its investment decision with respect to the
Note was made (if an entity) are located at the address immediately below the Purchaser&#8217;s name on the pertinent signature page of this Agreement, except as otherwise communicated by the Purchaser to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.5 <U>Brokers and Finders</U>. The Purchaser has not retained, utilized or been represented by any broker or finder in connection with the
transactions contemplated by this Agreement whose fees the Company would be required to pay. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.6 <U>Investment Representations and
Warranties</U>. The Purchaser hereby represents and warrants that, it as of the date of this Agreement is a &#8220;qualified institutional buyer&#8221; (as defined in Rule 144A under the Securities Act) or an institutional &#8220;accredited
investor&#8221; as that term is defined in Rule 501(a) under Regulation D promulgated pursuant to the Securities Act and has such knowledge and experience in financial and business matters as to be able to protect its own interests in connection
with an investment in the Note. The Purchaser further represents and warrants that (x)&nbsp;it is capable of evaluating the merits and risk of such investment, and (y)&nbsp;that it has not been organized for the purpose of acquiring the Note and is
an &#8220;institutional account&#8221; as defined by FINRA Rule 4512(c). The Purchaser understands and agrees that the offering and sale of the Note has not been registered under the Securities Act or any applicable state securities laws and is
being made in reliance upon federal and state exemptions for transactions not involving a public offering which depend upon, among other things, the bona fide nature of the investment intent and the accuracy of the Purchaser&#8217;s representations
as expressed herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.7 <U>Intent</U>. The Purchaser is purchasing the Note solely for the Purchaser&#8217;s own account and not for the
account of others, and not with a view to the resale or distribution of any part thereof in violation of the Securities Act, and the Purchaser has no present intention of selling, granting any participation in, or otherwise distributing the same in
violation of the Securities Act without prejudice, however, to the Purchaser&#8217;s right at all times to sell or otherwise dispose of all or any part of such Note in compliance with applicable federal and state securities laws. Notwithstanding the
foregoing, if the Purchaser is purchasing the Note as a fiduciary or agent for one or more investor accounts, the Purchaser has full investment discretion with respect to each such account, and the full power and authority to make the
acknowledgements, representations and agreements herein on behalf of each owner of each such account. The Purchaser has no present arrangement to sell the Note to or through any person or entity. The Purchaser understands that the Securities must be
held indefinitely unless such Securities are resold pursuant to a registration statement under the Securities Act or an exemption from registration is available. Nothing contained herein shall be deemed a representation or warranty by the Purchaser
to hold the Securities for any period of time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.8 <U>Investment Experience; Ability to Protect Its Own Interests and Bear Economic
Risks</U>. The Purchaser acknowledges that it can bear the economic risk and complete loss of its investment in the Securities and has knowledge and experience in finance, securities, taxation, investments and other business matters as to be capable
of evaluating the merits and risks of investments of the kind described in this Agreement and contemplated hereby, and the Purchaser has had an opportunity to seek, and has sought, such accounting, legal, business and tax advice as the Purchaser has
considered necessary to make an informed investment decision. The Purchaser acknowledges that the Purchaser (i)&nbsp;is a sophisticated investor, experienced in investing in private placements of equity securities and capable of evaluating
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
investment risks independently, both in general and with regard to all transactions and investment strategies involving a security or securities and (ii)&nbsp;has exercised independent judgment
in evaluating its participation in the purchase of the Note. The Purchaser acknowledges that the Purchaser is aware that there are substantial risks incident to the purchase and ownership of the Note, including those set forth in the Company&#8217;s
filings with the SEC. Alone, or together with any professional advisor(s), the Purchaser has adequately analyzed and fully considered the risks of an investment in the Note and determined that the Note is a suitable investment for the Purchaser. The
Purchaser is, at this time and in the foreseeable future, able to afford the loss of the Purchaser&#8217;s entire investment in the Note and the Purchaser acknowledges specifically that a possibility of total loss exists. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.9 <U>Independent Investment Decision</U>. The Purchaser understands that nothing in the Transaction Agreements or any other materials
presented by or on behalf of the Company to the Purchaser in connection with the purchase of the Note constitutes legal, tax or investment advice. The Purchaser has consulted such legal, tax and investment advisors as it, in the Purchaser&#8217;s
sole discretion, has deemed necessary or appropriate in connection with its purchase of the Note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.10 <U>Securities Not Registered;
Legends</U>. The Purchaser acknowledges and agrees that the Note is being offered in a transaction not involving any public offering within the meaning of the Securities Act, and the Purchaser understands that the Note has not been registered under
the Securities Act, by reason of its issuance by the Company in a transaction exempt from the registration requirements of the Securities Act, and that the Note must continue to be held and may not be offered, resold, transferred, pledged or
otherwise disposed of by the Purchaser unless a subsequent disposition thereof is registered under the Securities Act or is exempt from such registration and in each case in accordance with any applicable securities laws of any state of the United
States. The Purchaser understands that the exemptions from registration afforded by Rule 144 (the provisions of which are known to it) promulgated under the Securities Act depend on the satisfaction of various conditions including, but not limited
to, the time and manner of sale, the holding period and on requirements relating to the Company which are outside of the Purchaser&#8217;s control and which the Company may not be able to satisfy, and that, if applicable, Rule 144 may afford the
basis for sales only in limited amounts. The Purchaser acknowledges and agrees that it has been advised to consult legal counsel prior to making any offer, resale, transfer, pledge or disposition of any of the Note. The Purchaser acknowledges that
no federal or state agency has passed upon or endorsed the merits of the offering of the Note or made any findings or determination as to the fairness of this investment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Purchaser understands that the Note may bear one or more legends in substantially the following form and substance: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#8220;THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;SECURITIES
ACT&#8221;), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I)&nbsp;SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE
SECURITIES ACT, (II)&nbsp;SUCH SECURITIES MAY BE SOLD PURSUANT TO RULE 144, (III) THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO IT THAT SUCH TRANSFER MAY LAWFULLY BE MADE WITHOUT REGISTRATION UNDER THE SECURITIES ACT, OR
(IV)&nbsp;THE SECURITIES ARE TRANSFERRED WITHOUT CONSIDERATION TO AN AFFILIATE OF SUCH HOLDER OR A CUSTODIAL NOMINEE (WHICH FOR THE AVOIDANCE OF DOUBT SHALL REQUIRE NEITHER CONSENT NOR THE DELIVERY OF AN OPINION).&#8221; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.11 <U>No General Solicitation</U>. The Purchaser acknowledges and agrees that the
Purchaser is purchasing the Note directly from the Company. Purchaser became aware of this offering of the Note solely by means of direct contact from the Company as a result of a <FONT STYLE="white-space:nowrap">pre-existing,</FONT> substantive
relationship with the Company, and/or its respective advisors (including, without limitation, attorneys, accountants, bankers, consultants and financial advisors), agents, control persons, representatives, Affiliates, directors, officers, managers,
members, and/or employees, and/or the representatives of such persons. The Note was offered to Purchaser solely by direct contact between Purchaser and the Company and/or their respective representatives. Purchaser did not become aware of this
offering of the Note, nor was the Note offered to Purchaser, by any other means, and none of the Company and/or its respective representatives acted as investment advisor, broker or dealer to Purchaser. The Purchaser is not purchasing the Note as a
result of any general or public solicitation or general advertising, or publicly disseminated advertisement, article, notice or other communication regarding the Note published in any newspaper, magazine or similar media or broadcast over
television, radio or the internet or presented at any seminar or any other general solicitation or general advertisement, including any of the methods described in Section&nbsp;502(c) of Regulation D under the Note Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.12 <U>Access to Information</U>. In making its decision to purchase the Note, the Purchaser has relied solely upon independent investigation
made by the Purchaser, upon the SEC Reports and upon the representations, warranties and covenants set forth herein. The Purchaser acknowledges and agrees that the Purchaser and the Purchaser&#8217;s professional advisor(s), if any, have had the
opportunity to ask such questions, receive such answers and obtain such information from the Company regarding the Company, its business and the terms and conditions of the offering of the Note as the Purchaser and the Purchaser&#8217;s professional
advisor(s), if any, have deemed necessary to make an investment decision with respect to the Note and that the Purchaser has independently made its own analysis and decision to invest in the Company. Neither such inquiries nor any other due
diligence investigation conducted by the Purchaser shall modify, limit or otherwise affect the Purchaser&#8217;s right to rely on the Company&#8217;s representations and warranties contained in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Covenants</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.1
<U>Further Assurances</U>. Each party agrees to cooperate with each other and their respective officers, employees, attorneys, accountants and other agents, and, generally, do such other reasonable acts and things in good faith as may be necessary
to effectuate the intents and purposes of this Agreement, subject to the terms and conditions of this Agreement and compliance with applicable law, including taking reasonable action to facilitate the filing of any document or the taking of
reasonable action to assist the other parties hereto in complying with the terms of this Agreement. The Purchaser acknowledges that the Company will rely on the acknowledgments, understandings, agreements, representations and warranties contained in
this Agreement. Prior to the Closing, the Purchaser agrees to promptly notify the Company if any of the acknowledgments, understandings, agreements, representations and warranties set forth in <U>Section</U><U></U><U>&nbsp;4</U> of this Agreement
are no longer accurate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.2 <U>Listing</U>. The Company shall use commercially reasonable efforts to maintain the listing and trading of
its Common Stock on the Nasdaq Capital Market and, in accordance therewith, will use reasonable best efforts to comply in all material respects with the Company&#8217;s reporting, filing and other obligations under the rules and regulations of
Nasdaq. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.3 <U>Disclosure of Transactions</U>. The Company shall, by 9:00 a.m., New York City time, on the first (1st) Business Day
immediately following the date of this Agreement, issue a press release and/or file with the SEC a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (including, if applicable, all exhibits thereto, the &#8220;<B>Disclosure
Document</B>&#8221;) disclosing (i)&nbsp;all material terms of the transactions contemplated hereby and by the other Transaction Agreements and, if the Disclosure Document is a Current Report on Form <FONT STYLE="white-space:nowrap">8-K,</FONT>
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
attaching this Agreement and the other Transaction Documents as exhibits to such Disclosure Document, and (ii)&nbsp;all material <FONT STYLE="white-space:nowrap">non-public</FONT> information
concerning the Company disclosed to the Purchaser. Following the issuance or filing of the Disclosure Document, no Purchaser shall be in possession of any material <FONT STYLE="white-space:nowrap">non-public</FONT> information concerning the Company
disclosed to the Purchaser by the Company or its representatives. The Company understands and confirms that the Purchaser will rely on the foregoing representation in effecting securities transactions. In addition, unless it has already done so by
filing the Disclosure Document, on or before the fourth (4<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) Business Day following the date of this Agreement, the Company shall file with the SEC a Current Report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> disclosing all material terms of the transactions contemplated by this Agreement. Notwithstanding anything in this Agreement to the contrary, the Company shall not publicly disclose the name of the Purchaser or
any of its Affiliates or advisors, or include the name of the Purchaser or any of its Affiliates or advisors in any press release or filing with the SEC (other than any registration statement contemplated by the Registration Rights Agreement) or any
regulatory agency, without the prior written consent of the Purchaser, except (i)&nbsp;as required by the federal securities law in connection with (A)&nbsp;any registration statement contemplated by the Registration Rights Agreement and
(B)&nbsp;the filing of final Transaction Agreements with the SEC or pursuant to other routine proceedings of regulatory authorities, or (ii)&nbsp;to the extent such disclosure is required by law, at the request of the staff of the SEC or regulatory
agency or under the regulations of the Nasdaq Capital Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.4 <U>Integration</U>. The Company shall not, and shall use its
commercially reasonable efforts to ensure that no Affiliate of the Company shall, sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section&nbsp;2 of the Securities Act) that will be
integrated with the offer or sale of the Note in a manner that would require the registration under the Securities Act of the sale of the Note to the Purchaser, or that will be integrated with the offer or sale of the Note for purposes of the rules
and regulations of any National Exchange such that it would require stockholder approval prior to the closing of such other transaction unless stockholder approval is obtained before the closing of such subsequent transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.5 <U>Fees and Commissions</U>. The Company shall be solely responsible for the payment of any placement agent&#8217;s fees, financial
advisory fees, or broker&#8217;s commissions (other than for Persons engaged by the Purchaser) relating to or arising out of the transactions contemplated hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.6 <U>No Conflicting Agreements</U>. The Company will not take any action, enter into any agreement or make any commitment that would
conflict or interfere in any material respect with the Company&#8217;s obligations to the Purchaser under the Transaction Agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.7
<U>Indemnification.</U><U> </U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Company agrees to indemnify and hold harmless the Purchaser and its Affiliates, and their
respective directors, officers, trustees, members, managers, employees, investment advisors and agents (collectively, the &#8220;<B>Indemnified Persons</B>&#8221;), from and against any and all losses, claims, damages, liabilities and expenses
(including without limitation reasonable and documented attorney fees and disbursements and other documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses reasonably incurred in connection
with investigating, preparing or defending any action, claim or proceeding, pending or threatened and the costs of enforcement thereof) to which such Person may become subject as a result of any breach of representation, warranty, covenant or
agreement made by or to be performed on the part of the Company under the Transaction Agreements, and will reimburse any such Person for all such amounts as they are incurred by such Person solely to the extent such amounts have been finally
judicially determined not to have resulted from such Person&#8217;s fraud or willful misconduct. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Any person entitled to indemnification hereunder shall (i)&nbsp;give prompt written
notice to the indemnifying party of any claim with respect to which it seeks indemnification and (ii)&nbsp;permit such indemnifying party to assume the defense of such claim with counsel reasonably satisfactory to the indemnified party; provided
that any person entitled to indemnification hereunder shall have the right to employ separate counsel and to participate in the defense of such claim, but the fees and expenses of such counsel shall be at the expense of such person unless
(a)&nbsp;the indemnifying party has agreed in writing to pay such fees or expenses, (b)&nbsp;the indemnifying party shall have failed to assume the defense of such claim and employ counsel reasonably satisfactory to such person or (c)&nbsp;in the
reasonable judgment of any such person, based upon written advice of its counsel, a conflict of interest exists between such person and the indemnifying party with respect to such claims (in which case, if the person notifies the indemnifying party
in writing that such person elects to employ separate counsel at the expense of the indemnifying party, the indemnifying party shall not have the right to assume the defense of such claim on behalf of such person); and provided, further, that the
failure of any indemnified party to give written notice as provided herein shall not relieve the indemnifying party of its obligations hereunder, except to the extent that such failure to give notice shall materially adversely affect the
indemnifying party in the defense of any such claim or litigation. It is understood that the indemnifying party shall not, in connection with any proceeding in the same jurisdiction, be liable for fees or expenses of more than one separate firm of
attorneys at any time for all such indemnified parties. No indemnifying party will, except with the consent of the indemnified party, which consent shall not be unreasonably withheld, conditioned or delayed, consent to entry of any judgment or enter
into any settlement unless such judgment or settlement (i)&nbsp;imposes no liability or obligation on, (ii)&nbsp;includes as an unconditional term thereof the giving of a complete, explicit and unconditional release from the party bringing such
indemnified claims of all liability of the indemnified party in respect of such claim or litigation in favor of, and (iii)&nbsp;does not include any admission of fault, culpability, wrongdoing, or wrongdoing or malfeasance by or on behalf of, the
indemnified party. No indemnified party will, except with the consent of the indemnifying party, which consent shall not be unreasonably withheld, conditioned or delayed, consent to entry of any judgment or enter into any settlement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Conditions of Closing</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.1 <U>Conditions to the Obligation of the Purchaser</U>. The obligation of the Purchaser to consummate the transactions to be consummated at
the Closing, and to purchase and pay for the Note being purchased by it at the Closing pursuant to this Agreement, are subject to the satisfaction or waiver in writing of the following conditions precedent: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>Representations and Warranties</U>. The representations and warranties of the Company contained herein shall be true and correct in all
material respects, except for those representation and warranties qualified by materiality or Material Adverse Effect, which shall be true and correct in all respects, as of the date of this Agreement and as of the Closing Date, as though made on
and as of such date, except to the extent any such representation or warranty expressly speaks as of an earlier date, in which case such representation or warranty shall be true and correct in all material respects as of such earlier date, except
for those representations and warranties qualified by materiality or Material Adverse Effect, which shall be true and correct in all respects as of such earlier date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <U>Performance</U>. The Company shall have performed in all material respects the obligations and conditions herein required to be
performed or observed by the Company on or prior to the Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) <U>Consents</U>. The Company shall have obtained any and all
consents, permits, approvals, registrations and waivers necessary for the consummation of the purchase and sale of the Note, all of which shall be in full force and effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) <U>Adverse Changes</U>. Since the date of this Agreement, no event or series of events
shall have occurred that has had or would reasonably be expected to have a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) <U>Secretary&#8217;s
Certificate</U>. The Secretary of the Company shall have delivered to the Purchaser at the Closing Date a certificate certifying (i)&nbsp;the Restated Certificate of Incorporation; (ii)&nbsp;the Amended and Restated Bylaws; and
(iii)&nbsp;resolutions of the Company&#8217;s Board of Directors (or an authorized committee thereof) approving this Agreement, the other Transaction Agreements, the transactions contemplated by this Agreement and the issuance of the Note. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) <U>No Injunction</U>. No judgment, writ, order, injunction, award or decree of or by any court, or judge, justice or magistrate,
including any bankruptcy court or judge, or any order of or by any Governmental Entity, shall have been issued, and no action or proceeding shall have been instituted by any Governmental Entity, enjoining or preventing the consummation of the
transactions contemplated hereby or in the other Transaction Agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) <U>Deliveries</U>. The Company shall have delivered to the
Purchaser an executed copy of the Note in a form reasonably satisfactory to the Purchaser. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.2 <U>Conditions to the Obligation of the
Company</U>. The obligation of the Company to consummate the transactions to be consummated at the Closing, and to issue and sell to the Purchaser the Note to be purchased by it at the Closing pursuant to this Agreement, is subject to the
satisfaction or waiver in writing of the following conditions precedent: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>Representations and Warranties</U>. The representations
and warranties of the Purchaser in <U>Section</U><U></U><U>&nbsp;4</U> hereto shall be true and correct on and as of the Closing Date, with the same force and effect as though made on and as of the Closing Date and consummation of the Closing shall
constitute a reaffirmation by the Purchaser of each of the representations, warranties, covenants and agreements of the Purchaser contained in this Agreement as of the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <U>Performance</U>. The Purchaser shall have performed or complied with in all material respects all obligations and conditions herein
required to be performed or observed by the Purchaser on or prior to the Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) <U>Payment</U>. The Company shall have
received payment, by wire transfer of immediately available funds, in the full amount of the Purchase Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Termination</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.1 <U>Termination</U>. The obligations of the Company, on the one hand, and the Purchaser, on the other hand, to effect the Closing shall
terminate as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) upon the mutual written consent of the Company and the Purchaser that agreed to purchase a majority of the Note
prior to the Closing; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) by the Company if any of the conditions set forth in <U>Section</U><U></U><U>&nbsp;6.2</U> shall have become
incapable of fulfillment, and shall not have been waived by the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) by the Purchaser if any of the conditions set forth in
<U>Section</U><U></U><U>&nbsp;6.1</U> shall have become incapable of fulfillment, and shall not have been waived by the Purchaser; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) by either the Company or the Purchaser if the Closing has not occurred on or prior to
the fifth Business Day following the date of this Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">provided, however, that, in the case of clauses (ii)&nbsp;and (iii) above,
the party seeking to terminate its obligation to effect the Closing shall not then be in breach of any of its representations, warranties, covenants or agreements contained in the Transaction Agreements if such breach has resulted in the
circumstances giving rise to such party&#8217;s seeking to terminate its obligation to effect the Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.2 <U>Notice</U>. In the
event of termination by the Company or the Purchaser of its obligations to effect the Closing pursuant to <U>Section</U><U></U><U>&nbsp;7.1</U>, written notice thereof shall be given to the Purchaser by the Company. Nothing in this
<U>Section</U><U></U><U>&nbsp;7</U> shall be deemed to release any party from any liability for any breach by such party of the other terms and provisions of the Transaction Agreements or to impair the right of any party to compel specific
performance by any other party of its other obligations under the Transaction Agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Miscellaneous Provisions</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.1 <U>Public Statements or Releases</U>. Except as set forth in <U>Section</U><U></U><U>&nbsp;5.3</U>, neither the Company nor the Purchaser
shall make any public announcement with respect to the existence or terms of this Agreement or the transactions provided for herein without the prior consent of the other party (which consent shall not be unreasonably withheld). Notwithstanding the
foregoing, and subject to compliance with <U>Section</U><U></U><U>&nbsp;5.3</U>, nothing in this <U>Section</U><U></U><U>&nbsp;8.1</U> shall prevent any party from making any public announcement it considers necessary in order to satisfy its
obligations under the law, including applicable securities laws, or under the rules of any national securities exchange or securities market, in which case the Company shall allow the Purchaser reasonable time to comment on such release or
announcement in advance of such issuance, and the Company will consider in good faith the Purchaser&#8217;s comments. The Company shall not include the name of the Purchaser in any press release or public announcement (which, for the avoidance of
doubt, shall not include any filing with the SEC if so required by the applicable rules of the SEC) without the prior written consent of the Purchaser, except as otherwise required by law or the applicable rules or regulations of any securities
exchange or securities market, in which case the Company shall allow the Purchaser, to the extent reasonably practicable in the circumstances, reasonable time to comment on such release or announcement in advance of such issuance. Notwithstanding
anything to the contrary in this <U>Section</U><U></U><U>&nbsp;8.1</U>, Purchaser review shall not be required for Company disclosures that are substantially consistent with prior Company disclosures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.2 <U>Notices</U>. Any notices or other communications required or permitted to be given hereunder shall be in writing and shall be deemed to
be given (a)&nbsp;when delivered if personally delivered to the party for whom it is intended, (b)&nbsp;when delivered, if sent by electronic mail during normal business hours of the recipient, and if not sent during normal business hours, then on
the recipient&#8217;s next Business Day, (c)&nbsp;three (3) days after having been sent by certified or registered mail, return-receipt requested and postage prepaid, or (d)&nbsp;one (1) Business Day after deposit with a nationally recognized
overnight courier, freight prepaid, specifying next business day delivery, with written verification of receipt: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) If to the Company,
addressed as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">Rein Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">12407 N. Mopac Expy, Suite 250 #390 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">Austin, TX 78758 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">Attention:
Brian Windsor, President&nbsp;&amp; CEO </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">Email: bwindsor@reintx.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">Greenberg Traurig, LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">18565
Jamboree Road, Suite 500 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">Irvine, CA 92612 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">Attention: Daniel K. Donahue, Esq. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">Email: donahued@gtlaw.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)
If to the Purchaser, addressed as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman"><U></U><STRIKE></STRIKE><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U><STRIKE></STRIKE><U></U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">Attention: _____________ </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">Email: ________________ </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or such address as
subsequently modified by written notice given in accordance with this <U>Section</U><U></U><U>&nbsp;8.2</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.3 <U>Consent to Electronic
Notice</U>. The parties consent to the delivery of any stockholder notice pursuant to Section&nbsp;232 of the Delaware General Corporation Law, as amended or superseded from time to time, at the <FONT STYLE="white-space:nowrap">e-mail</FONT> address
set forth above. To the extent that any notice given by means of electronic mail is returned or undeliverable for any reason, the foregoing consent shall be deemed to have been revoked until a new or corrected
<FONT STYLE="white-space:nowrap">e-mail</FONT> address has been provided, and such attempted electronic notice shall be ineffective and deemed to not have been given. Each party agrees to promptly notify the other parties of any change in its <FONT
STYLE="white-space:nowrap">e-mail</FONT> address, and that failure to do so shall not affect the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.4 <U>Severability</U>. If
any part or provision of this Agreement is held unenforceable or in conflict with the applicable laws or regulations of any jurisdiction, the invalid or unenforceable part or provisions shall be replaced with a provision which accomplishes, to the
extent possible, the original business purpose of such part or provision in a valid and enforceable manner, and the remainder of this Agreement shall remain binding upon the parties hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.5 <U>Governing Law; Submission to Jurisdiction; Venue; Waiver of Trial by Jury</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York without regard to choice of laws
or conflicts of laws provisions thereof that would require the application of the laws of any other jurisdiction, except to the extent that mandatory principles of Delaware law may apply. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The Company and the Purchaser hereby irrevocably and unconditionally: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) submits for itself and its property in any legal action or proceeding relating solely to this Agreement or the transactions contemplated
hereby, to the general jurisdiction of the any state court or United States Federal court sitting in the Borough of Manhattan, City of New York in the State of New York; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii) consents that any such action or proceeding may be brought in such courts, and waives
any objection that it may now or hereafter have to the venue of any such action or proceeding in any such court or that such action or proceeding was brought in an inconvenient court and agrees not to plead or claim the same to the extent permitted
by applicable law; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iii) agrees that service of process in any such action or proceeding may be effected by mailing a copy thereof by
registered or certified mail (or any substantially similar form of mail), postage prepaid, to the party, as the case may be, at its address set forth in <U>Section</U><U></U><U>&nbsp;8.2</U> or at such other address of which the other party shall
have been notified pursuant thereto; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iv) agrees that nothing herein shall affect the right to effect service of process in any other
manner permitted by law or shall limit the right to sue in any other jurisdiction for recognition and enforcement of any judgment or if jurisdiction in the courts referenced in the foregoing clause (i)&nbsp;are not available despite the intentions
of the parties hereto; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(v) agrees that final judgment in any such suit, action or proceeding brought in such a court may be enforced in
the courts of any jurisdiction to which such party is subject by a suit upon such judgment, provided that service of process is effected upon such party in the manner specified herein or as otherwise permitted by law; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(vi) agrees that to the extent that such party has or hereafter may acquire any immunity from jurisdiction of any court or from any legal
process with respect to itself or its property, such party hereby irrevocably waives such immunity in respect of its obligations under this Agreement, to the extent permitted by law; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(vii) irrevocably and unconditionally waives trial by jury in any legal action or proceeding in relation to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.6 <U>Waiver</U>. No waiver of any term, provision or condition of this Agreement, whether by conduct or otherwise, in any one or more
instances, shall be deemed to be, or be construed as, a further or continuing waiver of any such term, provision or condition or as a waiver of any other term, provision or condition of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.7 <U>Expenses</U>. Except as expressly set forth in the Transaction Agreements to the contrary, each party shall pay its own <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> fees and expenses, including the fees and expenses of attorneys, accountants and consultants employed by such party, incurred in connection with the proposed
investment in the Note and the consummation of the transactions contemplated thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.8 <U>Assignment</U>. Neither party may assign its
rights or obligations under this Agreement or designate another person (i)&nbsp;to perform all or part of its obligations under this Agreement or (ii)&nbsp;to have all or part of its rights and benefits under this Agreement, without the prior
written consent of the other party; provided that the Purchaser may, without the prior consent of the Company, assign its rights to purchase the Note hereunder to any of its Affiliates or to any other investment funds or accounts managed or advised
by the investment manager who acts on behalf of the Purchaser (provided each such assignee agrees to be bound by the terms of this Agreement and makes the same representations and warranties set forth in <U>Section</U><U></U><U>&nbsp;4</U> ). In the
event of any assignment in accordance with the terms of this Agreement, the assignee shall specifically assume and be bound by the provisions of this Agreement by executing a writing agreeing to be bound by and subject to the provisions of this
Agreement and shall deliver an executed counterpart signature page to this Agreement and, notwithstanding such assumption or agreement to be bound hereby by an assignee, no such assignment shall relieve any party assigning any interest hereunder
from its obligations or liability pursuant to this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.9 <U>Confidential Information</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Purchaser covenants that until such time as the transactions contemplated by this Agreement and any material <FONT
STYLE="white-space:nowrap">non-public</FONT> information provided to the Purchaser are publicly disclosed by the Company, the Purchaser will maintain the confidentiality of all disclosures made to it in connection with this transaction (including
the existence and terms of this transaction), other than to the Purchaser&#8217;s outside attorney, accountant, auditor or investment advisor only to the extent necessary to permit evaluation of the investment, and the performance of the necessary
or required tax, accounting, financial, legal, or administrative tasks and services and other than as may be required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The
Company may request from the Purchaser such reasonable and customary additional information as the Company may deem necessary to evaluate the eligibility of the Purchaser to acquire the Note, and the Purchaser shall promptly provide such information
as may reasonably be requested to the extent readily available; provided, that the Company agrees to keep any such information provided by the Purchaser confidential, except (i)&nbsp;as required by the federal securities laws, rules or regulations
and (ii)&nbsp;to the extent such disclosure is required by other laws, rules or regulations, at the request of the staff of the SEC or regulatory agency or under the regulations of Nasdaq. The Purchaser acknowledges that the Company may file a copy
of this Agreement and the Registration Rights Agreement with the SEC as exhibit to a periodic report or a registration statement of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.10 <U>Third Parties</U>. Nothing in this Agreement, express or implied, is intended to confer on any Person other than the parties to this
Agreement any rights, remedies, claims, benefits, obligations or liabilities under or by reason of this Agreement, and no Person that is not a party to this Agreement (including, without limitation, any partner, member, shareholder, director,
officer, employee or other beneficial owner of any party to this Agreement, in its own capacity as such or in bringing a derivative action on behalf of a party to this Agreement) shall have any standing as a third party beneficiary with respect to
this Agreement or the transactions contemplated hereby. Notwithstanding the foregoing, the Indemnified Persons are intended third-party beneficiaries of <U>Section</U><U></U><U>&nbsp;5.9</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.11 <U>Headings</U>. The titles, subtitles and headings in this Agreement are for convenience of reference and shall not form part of, or
affect the interpretation of, this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.12 <U>Counterparts</U>. This Agreement may be executed in two or more identical
counterparts, all of which shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile or pdf signature including any
electronic signatures complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com shall be considered due execution and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original,
not a facsimile or pdf (or other electronic reproduction of a) signature. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.13 <U>Entire Agreement; Amendments</U>. This Agreement and
the other Transaction Agreements (including all schedules and exhibits hereto and thereto), together with any side letter agreements with the Purchaser, constitute the entire agreement between the parties hereto respecting the subject matter of this
Agreement and supersedes all prior agreements, negotiations, understandings, representations and statements respecting the subject matter of this Agreement, whether written or oral. No amendment, modification, alteration, or change in any of the
terms of this Agreement shall be valid or binding upon the parties hereto unless made in writing and duly executed by the Company and the Purchaser. The Company or the Purchaser may by an instrument signed in writing by such party waive the
performance, compliance or satisfaction by the other party with any term or provision of this Agreement or any condition hereto to be performed, complied with or satisfied by the Purchaser or the Company, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.14 <U>Survival</U>. The covenants, representations and warranties made by each party
hereto contained in this Agreement shall survive the Closing and the delivery of the Note in accordance with their respective terms. The Purchaser shall be responsible only for its own representations, warranties, agreements and covenants hereunder.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.15 <U>Contract Interpretation</U><U>.</U> This Agreement is the joint product of the Purchaser and the Company and each provision of
this Agreement has been subject to the mutual consultation, negotiation and agreement of such parties and shall not be construed for or against any party hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.16 <U>Arm</U><U>&#8217;</U><U>s Length Negotiations</U>. For the avoidance of doubt, the parties hereto acknowledge and confirm that the
terms and conditions of the Note were determined as a result of <FONT STYLE="white-space:nowrap">arm&#8217;s-length</FONT> negotiations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Remainder of Page Intentionally Left Blank.] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties hereto have executed this Agreement as of the day and
year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="77%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>COMPANY:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>REIN THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP>Name: Brian Windsor</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP>Title: President and Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>PURCHASER:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="5" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Title:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">S<SMALL>IGNATURE</SMALL>
P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> S<SMALL>ECURITIES</SMALL> P<SMALL>URCHASE</SMALL> A<SMALL>GREEMENT</SMALL> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF UNSECURED PROMISSORY NOTE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THIS
NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;ACT&#8221;), OR APPLICABLE STATE SECURITIES LAWS AND HAS BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION
THEREOF. THIS NOTE MAY&nbsp;NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN EXEMPTION THEREFROM UNDER THE ACT AND ANY APPLICABLE SECURITIES LAWS. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">$____________ </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For value received, Rein
Therapeutics, Inc., a Delaware corporation (the &#8220;<B>Company</B>&#8221;), promises to pay to ____________________ or its successors or assigns (&#8220;<B>Holder</B>&#8221;) the principal sum of US&nbsp;$__________ with simple interest on the
outstanding principal amount at the rate of zero percent (0%) per annum. All interest and principal shall be due and payable on the earlier of (a)&nbsp;June&nbsp;30, 2026 or (b)&nbsp;the date of the closing of the next issuance and sale of
securities of the Company, in a single transaction or series of related transactions, to investors resulting in gross proceeds to the Company of at least $10,000,000 (exclusive of the proceeds of this Note and the Other Notes) (the
&#8220;<B>Maturity Date</B>&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Note is one of a series of other unsecured promissory notes (&#8220;<B>Other Notes</B>&#8221;)
substantially in the form of this Note in the aggregate principal amount of up to $5,500,000, inclusive of this Note and an Other Note in the principal amount of $2,500,000 sold in January 2026. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.&nbsp;<U>Cash Purchase Price</U>. This Unsecured Promissory Note (the &#8220;<B>Note</B>&#8221;) is being purchased for a cash purchase price of
$_____________, inclusive of an original issue discount of 20%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. <U>Prepayment</U>. The then-outstanding principal and accrued interest (the
&#8220;<B>Note Balance</B>&#8221;) may be repaid in full or in part, without penalty, at the election of the Company at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. <U>Events of
Default</U>. Each of the following will be deemed to constitute an &#8220;<B>Event of Default</B>&#8221; hereunder: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;<U>Failure to
Pay</U>. The Company fails to pay the Note or any of the Other Notes on the Maturity Date; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;<U>Voluntary Bankruptcy or Insolvency
Proceedings</U>. The Company (i)&nbsp;applies for or consents to the appointment of a receiver, trustee, liquidator or custodian of itself or of all or a substantial part of its property, or voluntarily terminate operations, (ii)&nbsp;makes a
general assignment for the benefit of any of its creditors, (iii)&nbsp;is dissolved or liquidated in full or in part, (iv)&nbsp;commences a voluntary case or other proceeding seeking liquidation, reorganization or other relief with respect to itself
or its debts under any bankruptcy, insolvency or other similar law now or hereafter in effect or consents to any such relief or to the appointment of or taking possession of its property by any official in an involuntary case or other proceeding
commenced against it, (v)&nbsp;admits in writing its inability to pay debts as the debts become due, or (vi)&nbsp;takes any action for the purpose of effecting any of the foregoing; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;<U>Involuntary Bankruptcy or Insolvency Proceedings</U>. Proceedings for the
appointment of a receiver, trustee, liquidator or custodian of the Company of all or a substantial part of the property thereof, or an involuntary case or other proceedings seeking liquidation, reorganization or other relief with respect to the
Company or the debts thereof under any bankruptcy, insolvency or other similar law now or hereafter in effect are commenced and an order for relief entered, or such case or proceeding is not dismissed or discharged within 20 days of commencement;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;<U>Performance under Note</U>. The Company defaults in the due observance or performance of any covenant, representation,
warranty, condition or agreement on the part of the Company to be observed or performed pursuant to the terms hereof or any of the Other Notes, and such default is not remedied or waived within 15 calendar days after the Company receives written
notice of such default; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.&nbsp;<U>Remedies</U>. Upon the occurrence of an Event of Default, at the option and upon the written declaration of the Holder
(or automatically without such declaration if an Event of Default set forth in Section&nbsp;5(c)&nbsp;occurs), the entire Note Balance will, without presentment, demand, protest, or notice of any kind, all of which are hereby expressly waived, be
forthwith due and payable, and such Holder may, immediately and without expiration of any period of grace, enforce payment of all amounts due and owing under this Note and exercise any and all other remedies granted to it at law, in equity or
otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.&nbsp;<U>Governing Law</U>. The terms of this Note are governed by and construed in accordance with the laws of the State of Delaware. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.&nbsp;<U>Time of Essence</U>. Time is of the essence with respect to all of the Company&#8217;s obligations and agreements under this Note. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7.&nbsp;<U>Successor and Assigns</U>. This Note and all provisions, conditions, promises and covenants hereof are binding in accordance with the terms hereof
upon the Company, its successors and assigns. The obligations of the Company set forth herein will not be assignable by the Company without Holder&#8217;s prior written consent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8.&nbsp;<U>Collection Expenses</U>. The Company further agrees, subject only to any limitation imposed by applicable law, to pay all expenses, including
reasonable attorneys&#8217; fees, incurred by the Holder in endeavoring to collect any amounts payable hereunder which are not paid when due. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9.&nbsp;<U>Waiver</U>. The Company hereby waives presentment, protest, demand for payment, notice of dishonor, and any and all other notices or demands in
connection with the delivery, acceptance, performance, default, or enforcement of this Note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10.&nbsp;<U>Entire Agreement</U>. This Note is being issued
pursuant to a Securities Purchase Agreement (&#8220;Agreement&#8221;) between the Company and the Holder of even date herewith. The Agreement and this Note constitute the entire understanding of the Company and the Holder with respect to the subject
matter hereof and thereof and expressly supersede any and all prior agreements and understandings among them with respect to such subject matter. All pronouns contained herein, and any variations thereof, are deemed to refer to the masculine,
feminine or neutral, singular or plural, as to the identity of the parties hereto may require. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the Company has executed this Note as of February&nbsp;__, 2026.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>COMPANY:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>REIN THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>rntx-20260224.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release merge Build:20260112.3 -->
<!-- Creation date: 3/2/2026 10:19:10 AM Eastern Time -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2025"
  xmlns:rntx="http://www.aileronrx.com/20260224"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.aileronrx.com/20260224"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2025/naics-2025.xsd" namespace="http://xbrl.sec.gov/naics/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rntx-20260224_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rntx-20260224_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.aileronrx.com//20260224/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>rntx-20260224_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release merge Build:20260112.3 -->
<!-- Creation date: 3/2/2026 10:19:10 AM Eastern Time -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine3" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Three</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Three</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>rntx-20260224_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release merge Build:20260112.3 -->
<!-- Creation date: 3/2/2026 10:19:10 AM Eastern Time -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.aileronrx.com//20260224/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="rntx-20260224.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.aileronrx.com//20260224/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine3" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Feb. 24, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001420565<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 24,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">REIN THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-4196017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">12407 N. Mopac Expy.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">#390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Austin<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">78758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(737)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">802-1989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common stock: Par value $.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RNTX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d121919d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aileronrx.com//20260224/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d121919d8k.htm">d121919d8k.htm</File>
    <File>rntx-20260224.xsd</File>
    <File>rntx-20260224_lab.xml</File>
    <File>rntx-20260224_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d121919d8k.htm": {
   "nsprefix": "rntx",
   "nsuri": "http://www.aileronrx.com/20260224",
   "dts": {
    "inline": {
     "local": [
      "d121919d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "rntx-20260224.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/naics/2025/naics-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "rntx-20260224_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rntx-20260224_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 24
   },
   "report": {
    "R1": {
     "role": "http://www.aileronrx.com//20260224/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2026-02-24_to_2026-02-24",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d121919d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2026-02-24_to_2026-02-24",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d121919d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.aileronrx.com//20260224/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.aileronrx.com//20260224/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.aileronrx.com//20260224/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.aileronrx.com//20260224/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.aileronrx.com//20260224/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.aileronrx.com//20260224/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://www.aileronrx.com//20260224/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "terseLabel": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.aileronrx.com//20260224/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.aileronrx.com//20260224/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.aileronrx.com//20260224/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.aileronrx.com//20260224/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.aileronrx.com//20260224/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.aileronrx.com//20260224/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.aileronrx.com//20260224/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.aileronrx.com//20260224/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.aileronrx.com//20260224/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.aileronrx.com//20260224/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.aileronrx.com//20260224/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.aileronrx.com//20260224/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.aileronrx.com//20260224/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.aileronrx.com//20260224/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.aileronrx.com//20260224/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.aileronrx.com//20260224/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.aileronrx.com//20260224/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001193125-26-084012-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-26-084012-xbrl.zip
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MBAGU[%/;CI^CI:+-6I[C4%^R>OQC,YLL\I3&AU$LOH^Q%RU=+T;@UHMQN @
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M&\?YN%[#3%YW>(_W'FY^=$5]K=YY=*$.KN-LW*%(FDONM?K8Z)>#R2S);+3
M<;V^/AYX+E=ST/&*@KL"#2A0*D +37,T?7+RD( DIM/LJWBL%E8+\NF@1T\.
M//QMP@HB]]"3&!7C&[3H;N,TGXNK*RXK$EPP_'H*.F-=T)]@8F)@B/X-LJJ
MNQ1,KV@4I_P1"%W\3?$AYI]'$Y)"_(,)#AR-(0J4H'4SF\/*2W]0/CE_@O6
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MJ)XDO:<)(R8HQ^7"(KT)_W>:YQ77^=48N).'E5&9>MG)2!]#Z+156@<J/P]
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ME' 4^P4QQP32-NM$%477.IS*:6;G%_**2ET7 D6MH!K92=#J,>G.9879OTY
M6]WE?E#C.KGEY"]&,GJ)XP(A9HNDR\*0!SJM") P*\V(9;:#[\1EN@7N7/=
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M^F;ZR+:!C#=D.C8\5>UA.4-JO, V_874U$U81D0:>I546@VRHSQ.GX54LCG
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MEH/ 5OP0GR;2<P0.0!-+U[$_R$+G^%46_T'YODH,9N=0KU@FBC#&:R?YZ%2
M1K0\&JCM@B\B(:5+KV3<9-)_57O*&E.QDYA=/.V!H1S6D3DF30, ;O<1B%7H
MA_H;,W>*)C$\DAK%1?SPHI0(:V8G:M<C-237<U(J?RX'O,1-Z.8P8 ^]WY'1
M@9WC>+C-Y<%Q4U2IL0+;6YU+T#O9GEX157S#S$7W(I:/"5S!A2!2V!$N[)3-
M!AL9M3!$$ '1M4\%R24:.5RH(MYNOCDQC.@-) 4M$/$S=C5,Y+K52K.(A.+2
MHJ1?U1PP=.:ZX:<RZR,X!AKTF QHB9^96T'<L#Z?@?E]US2[1GF+W;'9@$<7
M[K'<KO+DN<5XA>5VPDJ[: 9F"'=@*DD&E_2")0QIJLV4X68'5TA4*PP\\6Q^
M+EK5Q$KXL2OA[7$6[6J96%Z*HQ#!''^48(Z7"V;178Q07BI$6=M)O;R^8 >K
MZSFS1E[]M>H?F]^8+C8* ]@MUEU%1HMAL%BK:)>5K-J-""/0[5GD^BLL=,3:
MA!U$P;@9Z >FOC,W'T]<& PQEBN_M8=8H7UK/7-<*MN2HCNTGL8L<:=1C,=9
MG5H-+Y_-ZHPYQ?OR,5P)5 9.)H^$D/,[*V7&@H2WXLC,M]W$&PG"'1YP$ Y]
M\S067>@^WRMA"4A;GJ%QKUQ;%17_(P&/4S^/"")OK!IBE3;5+XG^-#-,^HE]
M^]A.,I[;;A04_DG687>W\9&#9X_V*2@JI48VH2X?$G9;BZU<DL+!5>5>;&^=
MYI24<NW4\!0@AN$P6HHV8YPH11#QQQ0<]<JDMYFY(KYQR*ID[R;*^#B[CJ[%
M76AH*TNGLT0H(9\32*!*R%3;Z5Z<"V/,!,?F$!JBF.TMDGVD5./:8>7;)L*5
M2UJA+)&*5K1Y?-8Y]^)JQU)HC_95G8>Q@<"AEZ@/*\+L51DSVI'X':,&ZX6?
ME:<,TSQA%O3,]K!),6W<-R2@_/IANYI0AX9JU<R=S&W)**-D)K)=8EM5)UA2
M_:M_OFC,1E=N+9%6-[/*HX$(R9M9F:!W=^$33$4%>84Q8Y=6K^B,K_V)M1I7
M4"M3J49D%.<S^+5ZR9$]X9N;_%/<Y$M\:(,I^CXY=[?E.])GSUE&1\R*S1I_
M4C@2N%]2"69HH0))1)7!-&JWC-C!!XP4LS^$0; HZ_I1**J:3POHY#6TX&5D
MPG?5Y<Q\2 16-MLY) 0+4E>@TAT\WO^A=4FXT5,;,G6K LPX"D .8B^FK<_T
MUN/>WF+RSXW<_P]1QKPJ\@^X>"B;7B=$,;GN]:Y;Y]Z7.GJDV!$/JUO!'OTW
M>T<)BVZ$IM ^((""^JA</G'1E6BT=)J%"L&[E#<PX8\((W[1V)]&_K?UV1M*
M!' L+BZJ@]MJ%GV@=$\'5=J\;AIE9E;3]7=@U<?FXI=#Y]]8I 44>/@,^V%5
MU (;=ZY#3-OR(U/&3FD @L*NH83.M1DZ6>6AVT%;BDJ84ADYU4HZLM/"A.2;
ML6L(7#B $3UXA=&!@KUK],&[/(L7P=N(AL%UUS2/H -$W"';*0R_%LFC5 #T
MR6^$[=%(_AS_2840;Y.2_F#;LJ"UX'5 '5^RQME?9E(G(S<]ADYX9WH#AS>(
MJ62<S,7RS:P6:>I;H($FY!,.<0?N#;CX>28Y4]HZ4T=U13]+DUG"%C.-WBL,
MYU27]Y@&]3*CL![=1\O:#83+L+LI[R;),:J4*E8J#LZ&1\<8"3!>0$QUF8TX
M3T/W2$X%,"F6>([\Q>/@C/S!&'&"V3KQB+5-!3^GW#0F4(I/1\OUB!@0G."3
M$(S39T_<81I[5E]]E!=%#2KDN2GK9,S:)T]<LS:4W_[WGAD!/GFX?[!OR@,(
MQ[G.67OVE5G=F 0<K,_G,1&I>-VG;3"C\Y/:\T/[P6'=";MW1%\.?AAXA.6A
M">>:7 E)S7>M!H]^$HL1-H(-G3UU9CTT:6S41V'*HGR"X.!I\!Z6@S*ARECN
MNX-GCW^@J8%_/.&)/X\J,(4J,FKYDU=1]@&U(#C6"RX)S6P)[K;IGD.G&EQ>
MN!$)NJ.Y"8_7\;K(ZSE-47$-UK=R_6FN  76C6MPP#?Y551^P%V&L=TL:,K!
MT*(0:%MY*6OH)0,['S>TP7D@-7S"4 U8+DGQ;?W2O6MN#<*TL_M^SA[\ 1<<
M<[2Y>Y[NOFRA]:)N8V8F5G$*'[0$0X.R7E0JCD$YD6S<>%3-TYX>XCPF0+8D
MV!@$L=55E1?(.RKQVB"Z->D)UF+\$/G8]JI@B+VH-/:"_U3?.WVDO.IE9!B=
MVP)J>VO(/QT(68BHX5:=+T,KS7QA"3(2)2EV?X#^6>\WW5UH!<8;"U[ZI"6B
M[M&[CQVR4U[:*YS[&@0D"?38E?0#C-=HD'COQ\OWYS8J8-6.)X]!"R'W%UQ4
M#\@$?0X:#%F^\).7FU!X">Y^M!CA%F!S;KUT2.74<MS@B!T>WV1YFE\O-()%
M<_Y[G<PY/H1*1<W50811$!TD%7)P8!D2$+R@19(G;5KQO^YB>"?9QSZ/(@4M
MHRH:49Y-/ZO?57#)+_(K8KJ4 ,0\2-@CAFAH:@4.; G\R^8G4LVP+FOGSR&^
MU72 [H0PT].K(O\-DT1!':2Z+AC\&(&Z0LIA>J<:(%^/\ GH*)@C.H8K:TV2
M$!BWZD>QYL(E6G,: R!Q,>;T,,<^FM\L2B[91;O%8/LB1R#<QAW 02HB[3 T
M24:L0IX,<:5H@.CJI']&MQ$H)PP8P(A1<HL&#VDHQNO!4U<BHHB%O\>$:6^"
MF#?=]I:3#WOD/HK8:&^G$=Z8C$$S,]V;!3TZEM*28"::W8.-6MQ@S]#TXJ,\
M7]UWJ/%,X(*)LIXAV_.Q!L,7&2+->H[,O$[D<W457;/RX0;!@UJ<Q$2*.>;Q
M]43$;'?"H#6O=*-ZD^(ZF>0P$O#,T!NS'^A<UAR-M*^7%QB)O[XY8C_KY?>D
MBWV?-I:[9=;D!Z#KBB19Q=DD@IB@]R+XGO@0G8J@2SG&Q*Q1,@F7=8D QIUR
MK(=)P$5/Z44I>!2TG_(BNJ;<[8KMVM")*(?LL9NR;HRX%93<?@B18_#P A"+
M[CWL7,/G_(PC&;&-UO?0AB<\06@TA*#5*-NV5_#FY'P@%''#]X&&364]#7V"
MXSEVBV8?GU]X[]YQGQN^WPU.\SU/.P<3^8?O?WCR#(F!<?%L)3!KE1HKU5JF
M93V'&;66G%W7S@H8OJ'M.<L[DWBS2>-G?FZ1:\9P_0NIYV!,(E,6 %$>I D3
M.#(N4!UFBP5=4DN1RO[IL9-*=TR<E5SCJ.<@D%GL-!"NUI3H0D*^X#0::Z6=
MA?@J.?OU0ZP'S& LF #2 ZU)U_K!N"8EL'3O[3XDH+N6O8?6KID]!*V-3\^T
M+L1@IWO:;5'LQN2O,X^&QL(U._L*97Q6NW,)28\MWV:2- S 7!:A/7C\@CR4
ML2ELA2/F=&WFJ55_*.XQI6%>@(F63?+"$$BZO@>D\)'"ODHH*)*R%/QAH67L
M!1&! ;QVUZP*Y9 H))F.CJA]0:N?J,=)LE%"F6)S>+R2.^Z[K*[SI=WFE"SH
M^C/YJ-A0)^T])3#54%8NIP6>OTGFZHAQXYFX,9.2HE35G91"CF:Y3P/M<^;Z
M!+^AHB5Q 6_( Z]'S_&B6]=ZB0FNF$% ?YEMPQ@UO*GICX;+7E]!EP&_1/'3
M38#<,EY\_0VZ?,K</OOI2WKO:GZ/]@(*B;6!$K^T@!(2K.J(E]F E#E0'MJB
M:1+84)9%L"*QC7.TUHB7$0:#:Y 5M2$3I)VU,CO:1,-23BPYIG#&IY7)OO=Y
M>K1W0!'),\?%V36I",\G8DQ^#B4SD910U1J'HT1Y+ UI@459DOHA4^(G+3%6
MP?.R<NQ($] 8XXS$#7?BV[7N42V-P%0KKIN%HDF6N(+F.R?*CH4$I%T.)SP+
M=]8-\N6CPX_V"(WG<51U+05%A+7L$TV+LK+1[6!B)=US1>82.I3:H"O=D$*O
M:B6L?::TG.-)90!@D=QK_@S7E>_HPB4>I<*N4 861B'OE3_W@D&:VB&%ZM$G
M@M.B IT;!;AR$(@X)-VQ!:92#=:5L]M;W%[I-MA14RKRZQ.)7Y>,ESB%BUJB
MM6Z1S_XC_FDSROXGPA^[>CHWV@]X4 EF7H5,;1)_)2H'WECKC*P)4[ >Z^4C
MJIHR1,=E.D)"Q?'E&-H8_PGN))Y*!VWG3;6M8,I"(P7M4/#F6IW1,NBWV3MZ
MVXJX)1%WU#]MS^[FUM8+/;(FEQ'$F8YN!G,G"D_\-:Z^3"IAHRR$9*QJ&-//
MPC45AF$%1U'V 6.V8W)?EGEZR[FFTR*J89)EX+?Q ON#YKH?M9OA<815JF<*
MEU))T[(K44>B%YN4*E/!@4O,H_)KJZ8C[&=A +PHU:J%&VS<80]#*GYMK3C;
M-1D)W^&@DAF2>*]*2*;-8Q<K[/D&J"(?[1'L"E12M+C M*M$IW \06O+&UCD
MGE/8/+2A0E[I3P^)V[$5V>BQQ'XM*=0G$U:))4:[62#'6.: 7TNN<&/,@9KF
MUYC4,IP%$E=,(WRNU8\=;4@].&K)X4Z=R\B3&=LZF)^RRTI*Z'>%OKXFJD0I
MH1SQ/J;?VVQA^!G.6JJ]9"=TZ@1FR%XPL@)+(TNZ23XU$4YIF<O&!* 1,H32
M&F+");:]Q7>F)0O%VBM:R,"L@7-RL41&/JZ]S$EG3ZQ &R24/N?2OG(NNVR"
M>30GXV6T4, -'@GT<>";"C!IFO>VS;UR)7+HY-X[3DI<9P?D#4/]:IWKA]^<
MZY^&<G9N;[>$JX"#*\)"AG*_8"UQB<=-,3L-KO?8\(_:0M"AHC*X4J0I/ALR
M%LD4H.V")95A(^68KJ.6[FEO<R:E%%L$I81DP#JUC$C&BFSFLN:4XA!ZKK)U
M7&*CV,5QN$Q(CC<([I6(?G^3&!O-R7OVA2IGW'8J\M;"Z[Z(]G#'?^D;]A'[
M%% 1 "6GPXPR(<%"'L*YGC*.2:=W-\BU\#5AZU1-+P,G'TQ3YUIP%KJ;.:LL
M$N>=O(%3H1@E@/Y\BFZS>AA-)D1S[Z:NC6+*U.OL/9;3,D80;JX,^\18)Q3#
M5'2D(Y'6ZI0V<\A+*6Q=JTW:O2_N^GNT]W@I6KUM)3.>Z4^ F6]OW0-GCI4!
M2P04BF6B#B@^T2[9#!ZR: .) (_V?FBD6'9XX[:WK#NN<\)9K^OUOMU$*+K6
M\(N1F2A!A]_A%&H2K4N',ZH7? AZ4J>#@T>/!HYD:F:VD1>WT::\$FN+X!W"
ML!O. -0W18J CU$.MM_Z>/]@)Q)ULC^#I GU:R2VJ>N++A2+W59*@B*))7#D
MI55;Z ^(^(H.B%85T!M* 2TDP.\$L$G4=MXN%]XMFA^S(>2.07'67/AI79#*
MOVSE@YT_-$>0%G@<S5G!FP8Q4L]&QE2<P0"E!:3!==A;M2_L5=]9N,0-2>57
M#35NRF:J'VG58Y?XAR0TN2Z1P2@+3,:ONS<B9G!Q]H$N/6SYUR>G%P/> (\>
M'QSNC'>;4V2S$20.BIO=R:8P\/;./$EO9 [3:]_VUAA%,]JO(4%\S$3R$ZI'
M@>^F&XI21B4V2?D<+D" 6S'93J4RQ5I)R/32MWE*U%1@>S-"W<+W!8R+S!K4
M?B@A%K$:;S!;@PW5$4Q\@/'(0*XRF1)O4U:NEZV9>]EUUWMBC1BKX$P5E.+O
MY8)\6?'[1 M(9U6/\UW,=F_3EGF*ZH'N\/9PB4B;=RY-$I42XJ>IAA)]D=NR
MFOH,G_^ &,<,3("W);&+5$4RJEWKU@W=XQ;RHH;M#>J$I!OWM3+=R=(J_!^L
M:]+/K^G^$1*N9J)(HSJI[:?,68FJ$C*QKNB=L8.A+V I)*C_W^1W\6ULB8 [
MMA89\%Z,&8V".$U;W3)RB+\S$ZBB3ETR+01/*SO!.96-LXT1SPI_90(QM.@.
M>CQIJO@]NXSRS^ <UG#3%.PXN]84;8I4%^@:U'/)[@\B-@\[5IBXOEWE.2FQ
M[FN7^DR.'DX5X ;MKJ%6>N(;,X1BR ;W\\+"SF1LISXIGW^/6E62Z^XR]F^U
M^M2M=9I=3%>@,'#H;C 3RX[2ZJ;(ZVNN[M(D2UAVC9B[P]F\,_2W8#E.*B6
MX@CNJ(1LB#HC]RDS1=I?,,42\@UX6DGDY[":".F**V=I(BRJ=0PG36/:G3=:
M 8\#KC+[)99#YO UO')"77%7C1Q[K%HL6D8*I1$3)U^CBUI23:H)B0=P$Z+^
M:4/3'AJ5[D4P$.L;!B%XLN $]N79G:1U&1KB5XC''DHVPO;6!=8+Z+HXVKF;
MH"B-(]S@D:0N:TH#*5N12TRJ3LB&O:M@ F<3B<*Z6E>-0T=.A5BZ2MV,IGV7
M4[E?I17]D7@;EBN0I67R\%R@'Q($^/L0B5;LKL-QW7=W<2GI("?69["B>1G+
M./X06HT>3WH5>A*$9+&$F/RJ#-$?F-B.GFN)@WLO].(<'LB,)"!I[^BNH;&U
MG!6K-TK#IVXH/HAW,)_?8,Q_+'%&%ORAL^0TH4*GSW$7@J9A"!\A=&8E)!I3
M^INITSH0+]+7Z/M]^,WW^VF^7V<'\YE&^8LV!.6NA!3%(>B)D@!)]I]@D[5B
M4HN5T&F7[BFXK\C39PT8C[C"WZ5N'3(T(S 9A1GO3-^,IYDR>!Q!U9OHW!6>
MN^]AQ3-*Z3?ZG=0TE*)L!._4:1P3X-,4@=.WDPR^,S$;VQ<_YPX5V0;%0"OG
M CD94ULG5(!HB/( [9$9Y_-KCNB:,G?S(I\B4I5M[PGEG.^4NUT:I699$3=E
ME"X41( Z(N6LJ(SD.+1<"+W.#<[[LK5=S?2R4D[2#T06B2>GA98-)I5<W$4)
MV<<+;5"JE*"E2)_-4<%AK,"TK@@6KTZ;: K?<N_U0NXV0%!E+.)EPZKZ=Y&0
MU8TI,, \=*!@PPHX\8 <4WJI#XR3W(@+^!FK3_:$.:K4L5QN79I02W7.1 &5
M2>J)H7N)"!H[*3&4XSB.<[\<@^?D;=J+?;PEG6%Y%X<B*@)J!7GAKC+K"%V&
M"(7K4^PD*1Q."PW9)R>,]*O$AJ):>VQ["UT.CM$6TGM$4[=*2%YX0/B.(9/\
MZQ1U7UXC/]@7D*<*=^@(.F_%S?9B>^MM#!?+9+6&W>7:4[G!/C;E="-@BG,=
M-1UG* .;KK->HL'5SI5.PW&U;Y&II9K-CS3=TA@')1J.;;:EUB#9/&3;D)U*
MCGW86?6F<V1N_\GDU91\,0[(^N5LT84,3B<^%&O7IAW1AW-:P GA#5JN&C(7
M6^$P,:@CI\2P1[QKO&'ENB[;I/0FB"O!N3,D-P8Y(2A,W$5#W/#[-CR^XJ^3
M'!SAJ<PXV,%<"&OY'%P7<,O0YQN+1:/&8CB3Q.!4&L4D\ AEG#ZQZT5*>J=+
M/,@2^"SAQ>4T,FCBVZB05&-3C+2?^ -]!JQ8F&L9!(,X?)AW$;_4"LCB08CX
M[=ZF;:96F4"?&2A6<TLF<?\E[A(>6 BEY>PV^]F@#FCH"WLTR+%G=T!HEP!_
M;;6)[2U+)"64;<)LK4A"J4]X+XDG<1BN*(VWBK*YTTTDH$RT>\LXM8S/0F1E
MZ.!"<3>[R8%S83!JT5L[W!AK*<O;6UEN_*<X>*Z63(4WJ//SB*(!%/T@5QSF
MZH@"*<X%A5FI;'8O;<K%%E:\::+\4X51*N60F'P$9%.W*?N)ZVO90#+&&H>?
MY2YAM2+?!9SR/1E0A4MC:Z0+47*1<!AGBU DY+G6*M'/EPVT+^]!/D(#]/[C
ME"C?U9LA6B/O+TZN3H:7P<7P_&)XB6;P<?!F>#%\]6OP9O#S,#@]NPI>#8>G
M\,!/)Y=@),/W[T^/AQ=!HX'!T55P]CHX>/;P81@,X.]W0WCL.-C!Y^2=]O'M
M+7C>%K8^:S7W=O#+);8W./T5)F9P-<0_\)GWIR?81_KL<J_Y,^HS]7=P]#_O
M3["WKZ'QD].?AY=7T*,K:/ X>#?X50867)Z]/0Z#JXO!Z>7KX04^#X\/+B]/
M?CJED;X=7EX&.R=B[EZ^/WK3_3IG>O"%EX.WP^#\_<7E^P&\\^H,^PGWC#==
M(;3;US#V4'KG-7/Q'MH%D4:_/=FEX1^=O3O':7HSP&4\&I[\#)T8G 9GYR>G
M)V>G.'%'9^]/+X=OX>O!Y=GIX-5;F-3!U<GE:^C&V<6OV/()M/]F<!503W0^
MJ!^P%*_?OWU+'7HW.!X&OYQ<O3E[?R5COH"&X"U]FP(7=WMKY^1G&6GSB8NA
M-_O:]M'9Z>4)M,B-0_]@0(/7KT_>GLA>H'Z^@?F!M^*2!4?O+Z_.CD\&;V%I
MWYV<#H?!SB]O3N"AU[*[!C^?G1P/3H_HY\=G[U_!8-\,WN*LT%8)3H?P<F@.
MWXU;Y51^>#Q\"W,*TT3[4>=U=T]CXE^M=^[1-^_<9S:H#@3>WD4L_C%&E.]'
MZ8Q2&H):8UP8H)K][2@>8PR8G6-ZW79>XA):!PT6;2VZFR5AE )6XZKUGD!X
M.DG/(>CVRC('\R)^H,ESH58Y,!<G(D;=E%7K*W#H&RD/HY$U8JSYG178[@A6
M'%2/!7%H4C BHC I)HIP2BJK;9%&91S D;QCU](_JNK*0<Q&M/46PSTN&7%G
M0JSAE#1)6F:,3B:U?,(&I/<*$T&7/O ^,Q!,-;XQO&8)M\U*-Q98LX"=;>K3
MESH=\<DS6QG=MHE),A$-?IPW=R(&L]I;,23&W3L) ;&&V3&.4!&,XJK"7:N
MCJQ)_-FS<9JS&1%H."H[7$6A@Y2<Q*"J%UYO.@ L..H^> &Q'NBYR6PJ$)'
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MP=1/*>EL('=.,=1@G8+.@5?/.5A6SMF+W1QVPVEWN?-".4F4H#W5F_.B34I
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MT6S^(C@:GGWQ/@Y1ACP/1G?<L_^#UDSUQQY<%E^OB_G9-Q?S,B'X]+Y[1.X
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M7 #T0V!5\7D"2YD&@OE'J*> XC=HD(!.N;H0A^H IES%')$AK 7/S^Z;EL&
M.;T914@.K+(T8UA)ZQO B)B'1)E]",$3&.+2#.%)Q;[NN<MB+'/4#6KW1_TA
MCH:Y1UFZ_C",<'\V=<,G3PT[#/IE1RA3N%&'R/0Q.JR=+!_:77FW):5L))LM
M9! 2;I<@\).@=,C.YOS,:C;5NZ?Q2#/YF'@OYC,_-,U@_")+:KJ,X& OLL(O
M5S2Y[77GJ:"9G182&' 0(*[U@:&AHLG\*7-("CNN=H]$YH.<>/S0D1F=-&@X
M&@%UYA)K1:7/?SOBLHC@(W]*M? T](P$\- 42=N^&92$@?]>\4XKK\'1Z]"
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MJ^VY@&G'$TRM?.O-"/I^J!U]J>)(K3-]74B29A0\%.P$E G=>9C*:P]T0<$
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M(#KBHK[H7I1M0?X/BR.7P4%J!KK [%[>G#%?9B^N+OD'4$L! A0#%     @
M4C!B7 ;@?'Y%$0  &V8   X              ( !     &0Q,C$Y,3ED.&LN
M:'1M4$L! A0#%     @ 4C!B7$6O\K0(>0  SRH" !$              ( !
M<1$  &0Q,C$Y,3ED97@Q,#$N:'1M4$L! A0#%     @ 4C!B7(;J!8@] P
M3@L  !$              ( !J(H  ')N='@M,C R-C R,C0N>'-D4$L! A0#
M%     @ 4C!B7/7["K6>!@  MTD  !4              ( !%(X  ')N='@M
M,C R-C R,C1?;&%B+GAM;%!+ 0(4 Q0    ( %(P8EP@/EB V 0   ,N   5
M              "  >64  !R;G1X+3(P,C8P,C(T7W!R92YX;6Q02P4&
/  4 !0!  0  \)D

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>d121919d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="rntx-20260224.xsd" xlink:type="simple"/>
    <context id="duration_2026-02-24_to_2026-02-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420565</identifier>
        </entity>
        <period>
            <startDate>2026-02-24</startDate>
            <endDate>2026-02-24</endDate>
        </period>
    </context>
    <dei:SecurityExchangeName
      contextRef="duration_2026-02-24_to_2026-02-24"
      id="Hidden_dei_SecurityExchangeName">NASDAQ</dei:SecurityExchangeName>
    <dei:AmendmentFlag contextRef="duration_2026-02-24_to_2026-02-24" id="ixv-254">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2026-02-24_to_2026-02-24"
      id="Hidden_dei_EntityCentralIndexKey">0001420565</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2026-02-24_to_2026-02-24" id="ixv-265">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2026-02-24_to_2026-02-24" id="ixv-266">2026-02-24</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2026-02-24_to_2026-02-24" id="ixv-267">REIN THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2026-02-24_to_2026-02-24" id="ixv-268">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2026-02-24_to_2026-02-24" id="ixv-269">001-38130</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2026-02-24_to_2026-02-24" id="ixv-270">13-4196017</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2026-02-24_to_2026-02-24" id="ixv-271">12407 N. Mopac Expy.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2026-02-24_to_2026-02-24" id="ixv-272">Suite 250</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="duration_2026-02-24_to_2026-02-24" id="ixv-273">#390</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="duration_2026-02-24_to_2026-02-24" id="ixv-274">Austin</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2026-02-24_to_2026-02-24" id="ixv-275">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2026-02-24_to_2026-02-24" id="ixv-276">78758</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2026-02-24_to_2026-02-24" id="ixv-277">(737)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2026-02-24_to_2026-02-24" id="ixv-278">802-1989</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2026-02-24_to_2026-02-24" id="ixv-279">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2026-02-24_to_2026-02-24" id="ixv-280">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2026-02-24_to_2026-02-24" id="ixv-281">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2026-02-24_to_2026-02-24" id="ixv-282">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2026-02-24_to_2026-02-24" id="ixv-283">Common stock: Par value $.001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2026-02-24_to_2026-02-24" id="ixv-284">RNTX</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2026-02-24_to_2026-02-24" id="ixv-285">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
